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ABSTRACT 
Nicole Gabrielle Griffin: Genetic Analysis of Complex and Mendelian Diseases 
(under the direction of Kirk Wilhelmsen) 
 
This work describes approaches for discovering genetic variants that contribute to the 
etiology of human diseases with complex and simple modes of inheritance through the use of 
linkage analysis, genome-wide association analysis, and massively parallel sequencing (MPS). 
The studies contained in this work illustrate both the capabilities and limitations of these 
approaches.        
The two GWA studies in this work illustrated how reducing genetic and population 
heterogeneity could increase the ability to detect associations with genome-wide significance. 
The first, a GWA study of idiopathic Parkinson’s disease (IPD), was able to detect an association 
signal that approached genome-wide significance across chromosome 12q12, including the 
LRRK2 locus (average p-value=4.85 x 10
-6
), which has been implicated in IPD by several linkage 
studies. The second, a pilot GWA study of dystonia, identified an association with genome-wide 
significance at RNF213. The second half of this work employed MPS approaches to investigate 
the genetics of familial presentations of disease. The first, a study of a family with an atypical 
presentation of frontotemporal dementia with amyotrophic lateral sclerosis, was unable to detect 
an obvious deleterious mutation despite sequencing the exomes of 10 individuals and the whole 
genome of 1 individual in this family. The exome sequencing data from this family were used to 
perform a multipoint linkage analysis, which potentially implicated chromosome 9q in this 
family. In this region, all affected family members shared a synonymous mutation in CRB2, a 
 iv 
 
gene in the gamma-secretase pathway. The final study featured a genome-wide linkage analysis 
of a pedigree affected with a microcoria myopathy and a combined whole genome and whole 
exome sequencing analysis of this pedigree and 7 unrelated individuals. The linkage analysis 
found a multipoint LOD score of 1.8 on Chromosome 5q35. Exome sequencing detected a 
missense mutation shared by the affected family members in C5orf60: c.97C>T (p.P33S) that 
was also found in an exome from an unrelated subject. Another missense mutation in C5orf60, 
c.64G>C (p.D22H), was present in the exomes from 5 of the unrelated subjects. These results 
suggest that mutations in C5orf60 are a novel cause of microcoria and also corroborate the 
genetic heterogeneity of this condition. 
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Chapter 1 
Introduction 
 
An important goal of human genetics is the identification of sequence variants that 
produce traits of medical importance. Genetic variants that cause traits of interest occur with a 
wide range of frequencies and include changes as small as a single nucleotide to as large as a 
chromosomal duplication. To map variants to chromosome locations within the three billion base 
pairs that make up the human genome, researchers first used cytology to examine metaphase 
chromosomes for gross rearrangements. In most conditions, there are no visible rearrangements, 
such that cytology has been superseded by molecular biology and genetic techniques. Currently, 
the methods of choice for searching the genome include chromosome segregation analysis, 
which tests whether specific chromosome regions harbor sequence variants that transmit disease 
in families, or association analysis, which tests whether having specific variants is correlated 
with having a trait. With the development of technology for massively parallel molecular 
techniques and automation, it has become routine to systematically interrogate the entire genome 
by linkage and association analysis.  
 
1.1 Linkage Analysis 
Two loci are said to be linked if the hypothesis that they segregate independently is 
disproven. This typically occurs when two loci are on the same chromosome and are sufficiently 
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close that meiotic recombination between them does not occur frequently enough to make appear 
to segregate independently. The premise for linkage analysis of traits is that affected individuals 
in a pedigree are expected to have an increased probability of inheriting the same chromosome 
segments from common ancestors for the regions that have variants that lead to disease. For rare 
traits with simple modes of inheritance, there is a high probability that all the affected individuals 
in a family will inherit the causal sequence variants from the same common ancestors. The 
affected individuals in such a family are assumed to be identical by descent (IBD) for the causal 
variant. Because chromosomes are inherited from generation to generation with occasional 
meiotic recombinations, disease-causing variants will co-segregate with other markers on the 
same chromosome segment. Given enough affected individuals and pedigrees, linkage analysis 
can identify the region of the genome segregating with the disease variant. A typical 
chromosome region identified by linkage analysis will contain thousands of rare sequence 
variants that are effectively unique to the chromosome segment shared by the affected family 
members. Prior to the development of massively parallel sequencing strategies, linkage was 
followed by focused sequencing of coding sequences in the linked segment to look for mutations 
predicted to change the function of a gene product. The coding sequence of genes was the focus 
of investigations because it is often difficult to predict the effect of non-coding sequence changes 
and there was the prejudice that most trait producing sequence variants would affect the amino 
acids sequence of gene protein products.  
Initially, the criteria for deciding that sequence changes in a gene were responsible for a 
rare trait were: 1) that the putative causal variants are not found in a large sampling of unaffected 
individuals; 2) that the putative causal variants segregate with the trait in pedigrees; and 3) that 
independent variants could be detected in the same gene in pedigrees with the same condition. 
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Candidate gene resequencing has now been replaced by massively parallel sequencing such that 
the absence of other likely causal mutations in a linkage interval can be used to increase the 
likelihood that the gene responsible for a trait has been identified. 
To perform a linkage analysis, the minimum amount of information needed is a 
sufficiently large pedigree or collection of pedigrees with phenotype data and a set of genotyped 
markers. The type of analysis is determined by the characteristics of the disease inheritance and 
pedigree structure. For simple, Mendelian diseases where the mode of inheritance is well-
understood, parametric linkage analysis is usually pursued; in this type of analysis, the 
parameters describe the frequency of and mode of inheritance of disease. For diseases with 
complex modes of inheritance, so-called non-parametric linkage analysis is often used. The less 
parameterized or fitted parameter methods typically require large collections of families with at 
least an affected relative pair. For the microcoria myopathy study and frontotemporal dementia 
with amyotrophic lateral sclerosis (FTD-ALS) study described in this dissertation, parametric 
linkage analysis was used because the mode of inheritance could be inferred from the respective 
pedigrees. 
 
1.1.1 Design Considerations in Genetic Linkage Studies 
To test for co-segregation of a chromosome segment and a trait, it is necessary to be able 
to identify chromosomes that are identical by descent. In 1980, Botstein et al. (1) proposed that 
sequence variations specific to chromosome position, usually called markers, could be used to 
construct genetic maps and determine whether chromosome segments are identical by descent. 
Any sequence variation can potentially be used as a marker and a series of markers across a 
region can be used to increase the confidence that chromosome segments are IBD. Since the 
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concept of using DNA sequence variations as markers emerged, numerous assay methods have 
been developed. Botstein et al. (1) first defined the use of restriction fragment length 
polymorphisms (RFLP). RFLP-based approaches used restriction enzymes from bacteria to cut 
DNA into fragments through the recognition of a specific sequence. Sequence variations that 
create or destroy the recognition sequence for a restriction enzyme can be assayed by monitoring 
the cleavage pattern of DNA. Most RFLP polymorphisms are dimorphic and thus often cannot 
distinguish between chromosomes with the same allele. Collections of markers on a chromosome 
segment can overcome the limited ability of a single marker to distinguish between 
chromosomes. When the cost of genotyping a marker was high, markers with many alleles were 
preferentially used. The most commonly used highly polymorphic markers detected sequences 
with variable number tandem repeats (VNTRs). In most cases, VNTRs were assayed by 
measuring the size of a fragment between restriction enzyme cleavage sites or polymerase chain 
reaction primer binding sites. The development of array-based approaches allowed for the 
simultaneous genotyping of large collections of single nucleotide polymorphisms (SNPs) in a 
single assay. Currently, SNP-based approaches allow for the genotyping millions of markers in a 
single assay. The human population is estimated to have ten million SNPs where the less 
frequent allele has a frequency greater than 5% in a commonly studied population.  
Prior to collecting genotype data for linkage analysis, it is prudent to estimate the power to detect 
linkage. Frequently for pedigrees with simple modes of inheritance where sufficient genotype 
data will be obtained to confidently determine whether family members are identical by descent, 
power can be estimated by counting the number of informative meioses in the pedigree. For 
families with complex modes of inheritance, it is usually necessary to simulate genotype data 
using what is referred to as a gene-dropping approach (2). In this approach, the genotypes are 
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randomly assigned to the individuals for whom no ancestral data is available- the founders. 
Random segregation of the founders’ chromosomes is used to “drop,” or assign, the genotypes of 
the remaining members of the pedigree. The genotypes of the individuals that will not be 
genotyped are then removed. When pedigrees have already been ascertained the observed 
phenotypes and pedigree structures are used. Otherwise phenotypes are simulated using the 
parameters deduced from the observed mode of inheritance of the trait. The key parameters that 
need to be estimated are the number of trait loci, their allele frequencies, mode of inheritance and 
the effect size. For traits with simple modes of inheritance it is often assumed that there is a 
single trait locus with estimated allele frequencies and genotype penetrances. The genotype 
penetrance is the estimated fraction of the time that an individual with a trait genotype will 
express the trait. Linkage analysis is performed for the simulated data. The process is repeated 
over and over to estimate the null distribution for a linkage signal. The distribution can be 
compared to the distribution obtained where genotypes are simulated assuming linkage.  
Following this assessment of power, linkage between markers and a trait can be evaluated by 
several different tests. The Elston-Stewart and Lander-Green algorithms are the two standard 
methods for calculating the genotype likelihoods in pedigrees. Briefly, the Elston-Stewart 
algorithm evaluates the likelihood of the pedigree data using the probability of the founder 
genotypes, the probability of the phenotype given the genotype (i.e., the penetrance), and the 
probability of a child’s genotype given the parental genotypes (i.e., the transmission probability) 
(3). Because the offsprings’ genotypes can be collapsed or “peeled” onto the parent, this 
algorithm is better suited to handling large pedigrees; i.e., the complexity increases linearly as 
with the size of the pedigree and exponentially with the number of loci. In contrast, the 
complexity of the Lander-Green algorithm increases exponentially with the number of pedigree 
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founders and linearly with the number of loci. The Lander-Green algorithm incorporates a 
Hidden Markov Model (HMM) to determine the likelihood of the pedigree data given the 
inheritance vectors for each marker, the genotype probabilities for each marker, and the 
transition probabilities from one marker to the next (4).  
 
Tests for Genetic Linkage 
Parametric linkage analysis 
Parametric linkage analysis tests for segregation between a trait locus and a set of 
markers with known positions through the use of a specific trait model. Parametric models 
typically include the trait allele frequencies and genotype penetrances. Parametric linkage 
analysis can allow for age and gender specific penetrances that are either continuous or 
discontinuous functions. For traits with simple modes of inheritance, often called Mendelian 
diseases, the penetrance of disease associated genotypes are high and the penetrance of non-
disease associated genotypes are very low. By making simple assumptions, causal allele 
frequencies can be estimated based on the frequency of the trait in the population. Rare traits are 
predicted to be caused by rare alleles. Penetrances are inferred from the fraction of at risk 
individual in a pedigree that manifest the trait given the inferred mode of inheritance and 
genotype frequencies. 
Often by annotating the status (i.e., affected, carrier, unaffected, or unknown) of each 
individual in a pedigree, the particular mode of inheritance of a disease locus often becomes 
clear. For example, in an autosomal dominant mode of inheritance with complete penetrance, all 
individuals in a pedigree harboring one copy of the trait allele will express the trait; there will be 
male-to-male transmission, and approximately half of the offspring of an affected individual will 
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also be affected. Other modes of inheritance include autosomal recessive, X-linked, Y-linked, 
and mitochondrial. The observed mode of inheritance is used to develop the model used in 
parametric linkage analysis.  
Once the trait model is developed, the probability that a known genotyped marker is 
segregating with disease can be calculated. The logarithm-of-odds (LOD) score compares the 
probability that the pattern of genotypes would be seen if the marker locus and trait locus were 
linked to the probability that the pattern of genotypes would be seen if the marker locus and trait 
locus were not linked.  
 
Non-parametric linkage analysis  
Non-parametric linkage (NPL) analyses were developed to map loci of traits with 
complex inheritance. NPL studies analyze the amount of IBD sharing among affected individuals 
in pedigrees. The simplest form of NPL analysis is the affected sib-pair test, which requires 
genotype information from nuclear families with two affected siblings. The Haseman-Elston 
regression performs this sib-pair test by regressing the square of number of alleles shared IBD at 
a given locus against the square of difference in the quantitative phenotypes of the sib-pair (5). 
Variance components analysis, another form of NPL analysis, allows for the inclusion of 
components that might influence a trait, such as age or gender, to isolate the additive and 
dominance genetic effects for relatives with any type of familial relationship (6).  
 
1.1.2 Limitations of Genetic Linkage Studies 
For linkage analysis to be successful there must be sufficiently dense coverage of the 
genome with genotyped markers and sufficiently large and accurate pedigree information. For 
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parametric linkage analysis the disease variant must have sufficient penetrance to deduce the 
mode of inheritance for parametric linkage analysis, and there must be a sufficient number of 
informative meioses to uniquely specify the region of the genome that is segregating with the 
variant. 
Because the number of crossovers that typically occur on a single chromosome is small, 
the first major limitation of linkage analysis is that a linkage study typically does not provide the 
resolution necessary to determine the causal variant for a disease. By chance, it is possible for the 
critical recombination events to occur within close proximity, but most studies with the 
minimum power to detect linkage can narrow the genome to regions that are ten to twenty cM in 
size. Candidate gene resequencing was first used to search for causal variants after linkage was 
detected, but the advent of massively parallel sequencing technologies also allows for the 
identification of such variants. 
The other primary limitation of linkage analysis is that this type of analysis can only 
resolve the genetics of certain diseases. Diseases with complex inheritance are less easily 
resolved. While linkage analyses succeeded in mapping the genes for thousands of diseases, new 
approaches were needed to map the genes for the majority of human traits, which have complex 
modes of inheritance. 
 
1.2. Genome-wide Association Studies 
With the ability to genotype hundreds of thousands of markers at once came a new kind 
of genetic analysis: genome-wide association (GWA) analysis. GWA studies focus on common 
genomic variation which entail the genotyping of many markers with minor allele frequencies 
(MAF) typically greater than 5%. The underlying hypothesis is that common variation can be 
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responsible for common diseases. While linkage studies seek regions of the genome that are IBD 
in affected individuals, GWA studies seek to find alleles that are IBS. A significant association 
signal indicates that an allele occurs more frequently in individuals with the disease (i.e., the 
cases) than in individuals in the general population (i.e., the controls). Because markers located 
within proximity of each other on the same chromosome segment are more likely to be inherited 
together, certain combinations of alleles occur more frequently than would be expected simply 
by their frequencies in the population. This phenomenon is known as linkage disequilibrium 
(LD). In turn, because of this LD, association testing can identify direct associations at a given 
SNP and indirect associations with SNPs that were not genotyped but that are in LD with the 
genotyped SNP. The genotyped SNP is said to “tag” the SNPs with which it is in LD. 
Furthermore, the effect sizes of the variants implicated by GWA and linkage studies differ 
substantially. Most of the SNPs implicated in human disease by GWA analysis have small effect 
sizes. GWA analysis can pinpoint thousands of markers with small effect sizes as contributing to 
a phenotype, which can give a more complete view of that phenotype’s underlying biology. 
GWA studies have paved the way for the genetic analysis of common, complex diseases.   
The first published GWA study investigated age-related macular degeneration (ARMD) 
(7). ARMD is one of the most common causes of blindness or vision impairment in the elderly. 
While linkage had previously implicated a locus on chromosome 1q32, these researchers used 
data for 116,204 SNPs from 96 cases and 50 controls to find a significant association signal in 
this region for two SNPs in the gene for complement factor H (CFH). Another early success in 
the field of GWA studies was the association of the E4 allele of apolipoprotein-E (APOE) with 
the risk for late onset Alzheimer’s disease (LOAD). Prior to the advent of GWA studies, the 
Roses’ lab first provided evidence of linkage of LOAD to chromosome 19, and a candidate gene 
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study implicated the E4 allele (8-9). Following these discoveries, Grupe et al. (10) published a 
GWA study of 1,808 LOAD cases and 2,062 controls, who were genotyped for 17,343 SNPs, 
and found significant association signals for SNPs near APOE. This association has been 
confirmed by the majority of subsequent GWA studies of LOAD (11). 
Since these initial studies, shifts in the scale and scope of GWA studies have occurred. 
One of the first large-scale GWA studies was pursued by the Wellcome Trust Case Control 
Consortium (12) and involved 14,000 cases for 7 diseases and 3,000 shared controls. GWA 
studies can now entail tens or hundreds of thousands of individuals and approximately one 
million SNP markers. The largest GWA studies have focused on traits such as height and type 2 
diabetes. There are several considerations in designing a study of this scope.  
 
 
1.2.1. Design Considerations in Genome-wide Association Studies 
Power 
The first step in performing a GWA study involves the selection of the phenotype of 
interest and the collection of DNA samples from a population. The design of a GWA study will 
affect the  power to detect associations. Increases in power lead to decreases in type II error. 
Power depends on the number of samples, the frequency of the trait in the population, the ratio of 
cases to controls, the effect size of the association, and the disequilibrium between typed 
polymorphisms and the causal polymorphism. Power is becoming less of an issue as consortia 
are formed to tackle the genetics of some of the most common diseases; these study populations 
are often on the order of tens or hundreds of thousands of subjects.  
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Population stratification  
The subjects in a GWA study are often assumed to be unrelated. Failure to correct for 
kinship can inflate measures of association. It is possible to directly measure the relationship 
(kinship co-efficient) between study participants with a large collection of typed markers and 
correct measures of association for their relationship (13). However, it is also important that the 
subjects be derived from the same population. A more pernicious source of false association 
occurs when there is population substructure such that there is a correlation between phenotype 
and subpopulation membership. In the event that a study population is actually comprised of two 
or more sub-populations with significantly different minor allele frequencies and differences in 
disease frequency, a false positive association signal may arise.  
The most commonly used method for detecting stratification is genomic control (14). The 
genomic control statistic, , indicates the presence of the potential inflation of the association 
signals by dividing the average of the (Chi-squared) test statistics for approximately 50 SNPs by 
the median of this distribution. Several methods have been developed for identifying the sub-
populations within a study when stratification is present. These include structure-association 
based approaches, such as STRUCTURE (15), and principal component analysis-based methods, 
such as Eigensoft (16, 17).  
 
Adjusting for multiple testing 
While increasing the power of a study can lessen the likelihood of type II error, the 
potential for type I error is an equally pressing concern in GWA study design. Type II error (also 
called a false negative) results when the null hypothesis is incorrectly accepted, while type I error 
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(also called a false positive) results when the null hypothesis is incorrectly rejected. Each 
genotyped marker that is in equilibrium with other typed markers represents the testing of a 
different hypothesis. One statistical test used commonly in GWA studies is the Chi-squared test, 
which compares the allele counts or genotype frequencies in the cases and controls. For the 
purposes of the two GWA studies described in this dissertation, the Fisher’s exact test was used 
to compare the distribution of the genotypes for each SNP between the cases and controls 
because this test accounts better than the Chi-squared test for low allele/genotype counts. Thus, 
the p-values obtained from GWA studies have to be adjusted to account for hundreds of 
thousands of hypotheses. The most conservative of these adjustments is the Bonferroni 
Correction, which tests each hypothesis at a significance level of /n, where  is the probability 
of incorrectly rejecting the null hypothesis and n is the number of hypotheses, such that the type I 
error rate for the group of hypotheses as a whole is equal to . The generally accepted p-value 
cutoff for genome-wide significance is 5 x 10
-8 
(18). The Bonferroni correction is overly 
conservative when markers are not independent of each other. To illustrate the point, imagine 
that a large gene has hundreds of polymorphisms, but only two haplotypes. By testing whether a 
single SNP in the gene is associated effectively tests whether any of the SNPs in the gene is 
associated with the trait. To correct the threshold value for significance by the number of 
equivalent tests is obviously overly conservative.  
Even when adjusting for multiple comparisons, false positive results can still occur. The 
false discovery rate (FDR) describes the expected proportion of false positive results; Benjamini 
and Hochberg first described a method for controlling the FDR (19). One method for evaluating 
the appropriateness of adjustments for multiple comparisons is quantile-quantile (Q-Q) plotting. 
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A Q-Q plot compares the expected distribution of p-values under the null hypothesis with the 
observed distribution of p-values.  
 
Imputation 
It is estimated that there are ten million common (MAF > 0.01) SNPs in the human 
genome. Due to LD, it is possible to infer the genotypes of most common SNPs if the genotypes 
of approximately one million SNPs are known. Computational methods for imputing genotypes 
rely on haplotype phasing.  
Individuals within populations can be shown to be related by increased allele sharing that 
reflects population histories. Homogeneous populations tend to have unique LD structures, 
facilitating imputation, and the number of possible haplotypes for a gene is generally much lower 
than the number of possible haplotypes present in the population.  
When phasing haplotypes in a group of unrelated individuals, the inclusion of genotype 
information from more individuals results in a better estimation of the haplotypes (20). The 
majority of computational phasing approaches take into account the fact that most haplotypes in 
a population are similar to each other because of constraints on recombination and mutation over 
short distances; this observation forms the basis of approximate coalescent models and allows for 
hidden Markov model-based approaches to haplotype phasing. Once a set of haplotypes has been 
generated, these can be used to impute the genotypes for additional SNPs using the known 
genotypes and the knowledge of LD. PHASE (21), BEAGLE (22), MaCH (23), and IMPUTE2 
(24) are commonly used phasing methods; the latter three can also be used for genotype 
imputation based on phased genotypes.  
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Thus, through the use of genome-wide SNP arrays, more densely typed reference 
populations and imputation, it is possible to capture a substantial amount of genetic variation 
through a GWA approach.  
 
1.2.2. Limitations of Genome-wide Association Studies 
GWA studies have identified thousands of genetic markers that are associated with 
human disease. However, these studies do not seem to explain the majority of the heritability of a 
phenotype. For example, in 2010, Lango et al. published a GWA study of height with 183,727 
subjects of European descent and found significant associations for 180 loci (25). Because of its 
very large sample size, this study should have had sufficient power to detect associations. 
However, in the aggregate, these 180 loci explained only 10% of the variation in height. Because 
height is predicted to be 80-90% heritable, the findings of the study suggest that GWA studies 
are insensitive to much of the genetic variation that can explain a phenotype. This problem is 
known as the “case of the missing heritability.”    
Several explanations have been offered for this missing heritability. These explanations 
exemplify the limitations of GWA studies and are discussed below. 
 
Genetic and clinical heterogeneity 
Complex human diseases can be characterized by both genetic and clinical heterogeneity. 
Genetic heterogeneity can contribute to the problem of missing heritability because a given 
variant may only contribute to a phenotype in a portion of the cases. If this is the case, the 
association signal in the region containing this variant may not achieve genome-wide 
significance. Genetic heterogeneity can be divided into two types: locus and allelic 
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heterogeneity. The former occurs when variants in different genes result in the same phenotype. 
Locus heterogeneity is easier to define for loci with high genotypic relative risks, such as those 
that cause disease with simple modes of inheritance (e.g., Charcot-Marie-Tooth and 
spinocerebellar degeneration). There are many examples of apparently similar conditions that are 
due to mutations in different genes. Similarly often more than one mutation in a gene, i.e., allelic 
heterogeneity, can result in the same condition. For alleles and loci with smaller genotypic 
relative risks, the effects of genetic heterogeneity have a more nuanced effect on measured 
heritability. 
The occurrence of either locus or allelic heterogeneity can obscure an association signal 
in a GWA study by diluting the allele frequencies of SNPs. Genetic heterogeneity can be reduced 
by selecting a study group from a homogeneous population. 
In addition to genetic heterogeneity, clinical heterogeneity is problematic because while 
subjects might be classified as having the same disease, this classification may encompass a 
variety of distinct syndromes with similar symptoms. Thus, diseases that may be regarded as 
“common” may not be that common after all. Researchers have proposed focusing on 
intermediate phenotypes instead, such as using blood glucose levels as a proxy for diabetes, to 
lessen the possibility for phenotypic heterogeneity.  
 
The limitations of SNPs 
While SNPs are the most common type of polymorphism, many of the SNPs implicated 
by GWA studies do not cause a change in protein-coding sequence. Many SNPs associated with 
disease have been found outside of protein-coding sequences in introns or in intergenic regions, 
where their effects are unclear. It is also possible that an associated SNP can affect a gene that is 
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thousands of base pairs away. Furthermore, there are many types of variants beyond SNPs that 
are not tagged well in GWA studies. 
For example, researchers have also investigated the role of copy number variants (CNVs) 
in common disease. CNVs can constitute small or large insertions or deletions, as well as 
duplications, of DNA. While CNVs can be shared by individuals in a population, they can also 
occur as de novo mutations. Through the application of comparative genomic hybridization 
(CGH), researchers have identified de novo CNVs as playing a major role in autism spectrum 
disorders (26). 
Thus, the “missing heritability” may be explained in part by the inadequacy of SNPs in 
representing genetic variation throughout the genome. 
 
Gene-gene interactions 
In the case of complex diseases for which many genes have been implicated, the missing 
heritability may also arise from gene-gene interactions. That is, the etiology of a disease may be 
explained by a combination of alleles in different genes. However, it is computationally 
expensive and statistically burdensome to model all of the potential gene-gene interactions that 
could contribute to a phenotype. Moreover, these interactions are not captured by conventional 
GWA methods. 
 
Gene-environment interactions 
Gene-environment interactions may also contribute to the problem of the missing 
heterability. A gene-environment interaction arises when the contribution of a variant to a 
phenotype is influenced by an environmental exposure such that the combined effect of the 
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genotype and environmental exposure is greater (or less) than the sum of these factors’ 
individual effects. One possible consequence of a gene-environment interaction is that a variant 
only contributes to the risk for a phenotype in the portion of the population that has been 
introduced to a certain exposure; this interaction could potentially obscure an association signal. 
For example, researchers have investigated the extent to which physical activity may interact 
with common variants in FTO contribute to type II diabetes (27, 28).  As is the case for gene-
gene interactions, it would be computationally difficult and statistically burdensome to model 
these interactions in the context of a GWA study.  
 
Transgenerational epigenetic effects 
While SNP arrays can capture variation at the level of DNA sequence, the regulation of 
gene expression depends on more than just the primary sequence of nucleotides. Within nuclei, 
DNA is packaged as chromatin, which is wrapped around proteins known as histones to form 
nucleosomes. Histone modifications, such as methylation and acetylation, can either activate or 
suppress the transcription of genes into mRNA. These modifications, which collectively form the 
epigenome, are overlooked by GWA analysis because they do not alter the primary DNA 
sequence and may explain part of the missing heritability if they are passed from one generation 
to the next and contribute to the variation in a phenotype. 
 
1.2.3 Summary 
GWA studies, in concert with the International HapMap project, have thoroughly 
explored the common disease-common variant hypothesis and have described a vast amount of 
the common variation in the human genome. The approach has also explained a substantial 
proportion of the heritability of common diseases. However, just as the ability to genotype 
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common variants caused a shift from linkage analysis to GWA analysis, the ability to rapidly 
sequence the entire genome is causing a shift from GWA studies to sequencing studies to explain 
the genetics of disease. 
 
1.3. Massively Parallel Sequencing Studies 
On April 14, 2003, the Human Genome Project announced its completion. It had taken $3 
billion and 13 years to sequence the 3 billion base pairs in a single haploid genome. Ten years 
later, the diploid genome could be sequenced for approximately $5000 in a matter of days. In the 
near future, researchers hope to sequence an individual genome for less than $1000.  
This advancement was made possible the by the development of next-generation, massively 
parallel sequencing (MPS) technologies. (Sanger sequencing is regarded as the first generation of 
sequencing technology). As MPS technologies have become more affordable, researchers have 
increasingly made use of sequencing to identify variants in their subjects. MPS studies represent 
a significant shift in the scope of genetic analysis; these technologies allow the extension of 
linkage and association analysis to the scope of the full genome. However, because MPS 
approaches can identify nearly all the variants in an individual genome, it becomes more difficult 
to determine which variants are “important.” The pursuit of “private” variants that contribute to a 
disease with MPS studies signals a departure from the common variant-common disease model 
and a transition into the era of personalized medicine. To successfully identify the mutations that 
explain a particular phenotype, the scope of the study, sequencing platform, approach to variant 
calling, and variant interpretation are all important design considerations.  
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1.3.1. Design Considerations in Massively Parallel Sequencing Studies 
Sequencing Target 
While it is possible to sequence the whole genome, many researchers employ an 
approach that exclusively targets, enriches, and sequences the exome, i.e., the protein coding 
sequences of the genome. As described above, the focus on coding sequences can be partly 
explained by the difficulty that comes with trying to explain the effect of variants in non-coding 
sequences. While the exome comprises only 1 to 2% of the genome, it is predicted to contain 
85% of the variants that explain single-gene, Mendelian diseases. Substantial efforts have been 
made to develop efficient strategies for targeting these regions. Furthermore, sequencing only the 
exome can ensure better coverage of the sequenced regions and reduces the computational 
resources needed to call and analyze the variants. This approach was first successfully used by 
Ng et al. (29) to determine the causal variant for Miller syndrome using data from 4 individuals 
from 3 separate families, and exome sequencing has since been used to identify causal variants 
for many Mendelian diseases.  
Sequencing the exome, alone, however, may not be sufficient to find the variants that 
contribute to a phenotype. Even in the case of Mendelian diseases, it is possible that the causal 
variant resides outside of the exome or is not adequately targeted by current exome enrichment 
strategies. Furthermore, the analysis of sequenced variants may exclude variants that do not 
cause a change in the predicted amino acid sequence. Thus, researchers should use the 
characteristics of their disease of interest to determine whether whole genome sequencing or 
exome sequencing should be used. For Mendelian diseases with a known mode of inheritance 
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and for which the causal variant is suspected to have a high penetrance, exome sequencing can 
be more effective and less costly than whole genome sequencing.    
 
 Sequencing Platform 
Several technologies have been developed in the field of next-generation sequencing. 
MPS is high-throughput and massively parallel, meaning that thousands of bases can be 
sequenced simultaneously. The sequencing studies of microcoria myopathy and FTD-ALS 
described in this dissertation made use of the Illumina (Solexa) sequencing platform. The 
underlying principle of this technology is sequence-by-synthesis. The Illumina platform makes 
use of flow cells; the surfaces of these flow cells are covered with a lawn of special primers to 
which genomic DNA fragments are ligated. The fragments are sequenced using a process called 
cyclic reversible termination. Briefly, the attached DNA fragments are amplified with 
fluorescent dye-labeled nucleotides to form clusters of DNA fragments, which are imaged, 
allowing the calling of nucleotides. Other sequencing platforms include those developed by 
Roche (454), Helicose Bioscences, Pacific BioSciences, and Life Technologies (SOLiD and Ion 
Torrent).  
 
Sequencing alignment and variant calling 
Once the sequence reads have been produced, the next step involves aligning the reads to 
a reference genome. Many software tools have been developed to perform this task. Most of 
these methods rely on indexing the reads, the reference genome, or both. The earliest aligning 
tools used hashing to create these indexes. However, this form of indexing is memory-intensive, 
which prompted the development of diverse algorithms to minimize the needed computational 
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resources. Several of these algorithms make use of the Burrows-Wheeler transformation to 
compress the sequence information and perform the alignment.  
A second crucial computational task involves the calling of genotypes once the sequence 
reads have been aligned. This process takes into account, at the bare minimum, the number of 
reads for a given nucleotide and the quality of these reads at each position in the genome. 
Probabilistic methods for variant calling take into account other information, such as LD 
structure and allele frequencies, to make genotype calls (30).   
 
Variant interpretation 
Once the variants in an individual have been called, the next task is to determine which of 
these contribute to the phenotype of interest. Software tools, such as Polyphen, can predict 
whether a variant has the potential to cause a change in protein sequence or structure. However, 
variants might be excluded from analysis if it is unclear how they affect the product of a gene. 
 
1.3.2. Limitations of Massively Parallel Sequencing Studies 
Read length 
The majority of sequencing platforms produce reads that are in the range of 100 
nucleotides in length. The short length of these reads can result in mis-alignment or unplaced 
reads, leading to a loss of data. Read length will become less of an issue as the technology is able 
to synthesize longer reads.  
     
 
 
 22 
 
Resolving copy number variants and repetitive regions 
Because MPS relies on reference genomes, this method is not as adept at resolving 
mutations that more than a few nucleotides in length. In the case of cancer, for example, large 
chromosomal rearrangements are not uncommon, and these rearrangements are difficult to 
capture with standard genome alignment tools. Despite these challenges, MPS technologies will 
continue to advance the field of genetics and enable the development of personalized medicine.   
  
1.4 Chapter Overviews 
The studies contained within this manuscript highlight the use of the approaches 
described above. Chapters 2 and 3 describe two GWA studies that were performed in the 
Ashkenazi population. Chapter 2, a study of idiopathic Parkinson’s disease, illustrates how 
genetic heterogeneity can obscure association signals. Chapter 3 presents a pilot GWA study of 
dystonia, a movement disorder. Chapters 4 and 5 focus on the use of MPS technologies. Chapter 
4 describes the use of exome sequencing to analyze a familial presentation of frontotemporal 
dementia with amyotrophic lateral sclerosis (FTD-ALS). Chapter 5 describes a genome-wide 
linkage analysis of a pedigree affected with microcoria myopathy and a combined whole genome 
and whole exome sequencing analysis of this pedigree and 7 unrelated individuals. Finally, 
Chapter 6 provides conclusions and future directions for the studies as well as insights for the 
future of human genetic analysis. 
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Chapter 2 
A Genome-wide Association Study of Idiopathic Parkinson’s Disease 
2.1 Introduction 
As the one of the most common neurodegenerative diseases, idiopathic Parkinson's 
Disease (IPD) is a debilitating disease presenting with chronic, progressive difficulty with motor 
function. While the symptoms of the disease can be managed, its progression cannot. IPD is 
estimated to affect 1% to 2% of the population over 65 and can occur in families or sporadically. 
Despite the identification of some environmental factors and numerous genetic studies, the 
etiology of this disorder is largely unexplained in greater than 95% of cases. The study of the 
disease is further complicated by genetic and phenotypic heterogeneity; this phenotypic 
heterogeneity is evidenced by the presence of both early-onset and late-onset forms of the 
disease. The disease can also be monogenic or polygenic. Thus, substantial effort is needed to 
determine the genetic causes of this disease.  
Family-based linkage studies, which have the ability to identify rare variants with high 
penetrance, constituted some of the first attempts to identify genes that cause IPD. 
Polymeropoulos et al. (1, 2) mapped the first IPD susceptibility locus to chromosome 4q21-23 in 
an Italian kinship, which they later deduced to be a mutation in the gene for alpha-synuclein 
(SNCA). Since this study, the following loci have been identified as linked to the disease: PARK3 
(3), PARK5/UCHL1 (4), PARK8/LRRK2 (5), PARK10 (6,7), PARK11 (8), PARK2/SOD2 (9-12), 
PARK7/DJ1 (13,14), PARK15/FBXO7 (15), and PARK12 (8). Among the genes identified, 
leucine-rich repeat kinase 2 (LRRK2, 12q12) was first linked to IPD using a family-based linkage 
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study in a Japanese family (5). Subsequently, a moderate penetrant (G2019S) mutation in LRRK2 
was identified in several populations that would not have been detected by conventional linkage 
analysis; the G2019S mutation is estimated to have a 30% lifetime penetrance (16).  
While these linkage studies could elucidate the etiology of IPD in select families, new 
methods were needed to begin the task of identifying the causes of most cases of IPD. 
Approximately 15% of IPD cases are familial, while the rest are sporadic. With the advent of 
genome-wide single nucleotide polymorphism (SNP) genotyping platforms, researchers began 
looking for common variants that contribute to IPD. Such genome-wide association studies 
(GWAS) have the ability to identify common variants that contribute to the risk for a disease, 
and it was hoped that because IPD is a common disease that common variants could explain the 
etiology of the disease. The first IPD GWAS, performed by the Linked Efforts to Accelerate 
Parkinson's Solutions (LEAPS), studied 443 discordant sibling pairs with 332 case-unrelated 
control pairs and identified 11 SNPs as likely to be associated with IPD (17). The second major 
GWAS, performed by the National Institute of Neurological Diseases and Stroke (NINDS), 
tested 547 unrelated individuals and was not able to replicate the LEAPS findings (18). Because 
of its detection in many different linkage studies, GWAS researchers had expected to find a 
significant association at LRRK2. Neither the LEAPS study nor the NINDS study was able to 
detect polymorphisms near LRRK2 as being associated with IPD. A meta-analysis of 3,458 cases 
and 3,719 controls from 10 different populations conducted by the Genetic Epidemiology of 
Parkinson’s Disease (GEOPD) was also unable to replicate the findings of these studies (19). 
The conflicting results from these studies raised skepticism about the ability to find susceptibility 
loci for sporadic IPD under the common disease-common variant model implicit to GWAS. 
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This inability to discover associated loci could be explained by the fact that these studies 
did not satisfy certain conditions. For loci to have significant association signals in a GWAS, 
there needs to be sufficient allelic and locus homogeneity such that the genotyped markers are in 
LD with the causal allele(s). In the case of a polygenic disorder such as IPD, this condition is 
difficult to achieve. Also, the effect of an associated variant has to be modest in size, and the 
variant has to have a relatively high frequency. The study population needs to be homogeneous; 
population substructure, the presence of two or more groups with different genetic backgrounds 
in a study, can cause false positive signals that obscure true associations and be a source of locus 
heterogeneity. Because of their small sample sizes and heterogeneous populations, previous IPD 
GWAS were under-powered to detect variants that contribute to IPD.  
In order to increase power, it will be necessary to increase sample size and reduce locus 
heterogeneity. GWA studies of other very common complex, multifactorial diseases, including 
type 2 diabetes and coronary artery disease, now involve tens to hundreds of thousands of 
samples genotyped at over a million markers to search for causative mutations. An alternate 
approach is to increase power by focusing on specific populations with a shared genetic 
background; the underlying logic is that individuals with a disease in the same population will 
have inherited disease-causing variants from common ancestors.  
This claim is supported by two  GWA studies performed in different populations; the first 
of these was a study conducted by Satake et al. in 2,000 cases and 18,000 controls in a Japanese 
population in which the researchers were able to detect a significant association on a genome-
wide level for LRRK2, which is a very promising finding (20). The second study was conducted 
by Simon-Sanchez et al. in a European population of 3,000 cases and 4,000 controls, and the 
association signal at LRRK2 was not significant (21). Because these studies incorporated large 
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sample sizes, they had substantial power to detect associations. Both of these studies were able to 
identify associated loci with genome-wide significance; Satake et al. found a novel risk locus, 
which they named PARK16, as well as SNPs in BST1, SNCA, and LRRK2 to be associated with 
IPD in their Japanese study population, while Simon-Sanchez et al. found SNPs in SNCA, 
MAPT, and PARK16 to be significantly associated in their European study population. The 
largest IPD GWAS to date, which was conducted by Do et al. in individuals of European 
descent, consisted of 3,426 cases and 29,624 controls (22). This study identified two novel 
associations with genome-wide significance at SCARB2 and SREBF1/RAI1 and confirmed 
associations at LRRK2, GBA, SNCA¸MAPT, GAK, and the HLA region. Thus, these studies 
indicate that genetic heterogeneity within the study population and the inability of common 
SNPs to “tag” the G2019S mutation, and not simply a lack of power, prevented previous IPD 
GWAS from finding an association signal at LRRK2.  
In the European population, studies have suggested that G2019S-positive individuals 
with late onset IPD share a common haplotype (23). The most recent estimates suggest that this 
mutation arose from a common ancestry some 2500 years ago (24). This claim is supported by 
the observation that G2019S mutations are far more common in the Ashkenazi and Middle 
Eastern/North African populations than in the general European populations (25).  
The Ashkenazi population is unique in that it features haplotypes that are European and 
North African in origin (26). In this population, G2019S mutations are associated with 10 and 
28%, respectively, of sporadic and family history positive patients. The best estimate of the 
cumulative risk of IPD for G2019S carriers is 36% at 59 years, 59% at 69 years, and 80% at 79 
years (27). By examining this population separately in a GWAS for causative polymorphisms, 
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this study will have increased power to detect therapeutic targets for IPD and contribute to the 
search for more effective treatments for this debilitating disease.  
Thus, a small, prospective GWAS in the Ashkenazi, followed by a larger replication 
GWAS, was performed to look for common variants that could explain the genetics of IPD in 
this population. While the initial GWAS was unable to detect an association signal near LRRK2, 
the replication GWAS was able to detect a strong association signal across this region that 
approached genome-wide significance. On chromosome 12q12, several SNPs in the genes 
CNTN1 and SLC2A13 also approached genome-wide significance.      
 
2.2 Methods 
Samples 
For the initial phase, a GWAS was conducted in an Ashkenazi population from New 
York consisting of 25 LRRK2-G2019S positive individuals, 96 IPD cases, and 96 controls. The 
replication phase of the study consisted of 166 IPD cases and 1,436 controls. The cases included 
50 individuals that were known LRRK2 G2019S mutation carriers. The controls included 105 
dystonia patients, 407 schizophrenia patients, 273 Crohn’s disease patients, and 651 healthy 
controls.  
Only individuals with 4 Ashkenazi grandparents were included in the study. The IPD 
cases were confirmed by Dr. Susan Bressman, a movement disorder specialist, and were 
obtained in collaboration with Dr. Laurie Ozelius of the Mount Sinai School of Medicine. Family 
history information was collected from each patient, and none of the subjects included in the 
analysis was known to be related or had a measured pair-wise kinship coefficient greater than 0.1 
with another participant (i.e., less related than first cousins) as measured with the PLINK 
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software package (28). In the replication study, 5 cases and 32 controls were excluded based on 
relatedness. 
 
Genotyping 
For the first phase of the study, the samples were genotyped on the Affymetrix GeneChip 
Human Mapping 500K SNP array. The genotype calls were made using the Birdseed V2 
algorithm included in the Affymetrix Genotyping Console Software package. For the replication 
phase of the study, all samples were genotyped on the Affymetrix Genome-Wide Human SNP 
Array 6.0 platform according to the manufacturer’s protocol, and the genotype calls were made 
using the Birdseed V2 algorithm.  
 
Quality control of SNP Genotyping and Association Analysis 
Standard quality control measures were used to filter the genotyping calls with the 
PLINK software. Only SNPs with a minor allele frequencies > 0.05 and genotyping rates > 90% 
that did not violate Hardy-Weinberg equilibrium were included in the association analysis.  After 
removing these SNPs, 357,319 markers and 634,338 markers remained in the initial study and 
the replication study, respectively. The p-values for the association of each of the SNPs in the 
initial study were calculated by comparing the distribution of the genotypes between the cases 
and controls with a Fisher’s 2x3 exact test. The association analysis for the replication study was 
performed for the genotyped and imputed SNPs (see below) for the replication study using the 
mach2dat tool in the MaCH software package. An association was considered to have genome-
wide significance if the p-value was less than 2.0 x 10
-8
; this threshold was determined using 
Bonferroni’s correction (p = 0.05/2,500,000 markers).  
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To reduce type I error that resulted from aggressive genotyping calling by the Birdseed 
algorithm, the fluorescent probe intensities for each allele for each genotype were plotted for 
SNPs with p-values that were less than 1.0 x 10
-5
. These scatter plots were used to determine if 
the genotype calls had been made inappropriately.  
 
Imputation 
For the replication phase of the study, additional genotypes were imputed using MACH 
(MArkov Chain Haplotyping) (29, 30). A set of reference haplotypes was created using the 
HapMap2 CEU population after first ensuring that the alleles from the current study matched the 
HapMap alleles for SNPs that were found in both data sets (i.e., that they were genotyped on the 
same strand). The genotypes from the HapMap data were phased to produce a set of reference 
haplotypes with the following parameters:  --rounds 20, --states 300, --phase, --interim 5, --
sample 5, --compact. 
Then, this set of reference haplotypes was used to impute additional markers with the 
following options in MaCH: --rounds 5, --states 200. For genotype inference, only SNPs 
genotyped on the Affymetrix platform with genotyping rates > 90% and minor allele frequencies 
> 5% that did not violate Hardy-Weinberg equilibrium (p< 0.000001) were included in the input 
files.  
 
Analysis of Population Stratification 
Population stratification is known to confound the results of association studies. To 
assess population stratification, the genomic control inflation factor, , was calculated by 
selecting a subset of 50 SNPs from the replication GWAS data that were in linkage 
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disequilibrium with each other. The median of the observed chi-squared distribution of the 
association values for these SNPs was divided by the expected median of this distribution to 
obtain a value of 1.04, which was indicative of negligible population stratification. 
To further rule out population stratification, principal components analysis was 
performed in EIGENSTRAT (31) by comparing the study population with the CEU and YRI 
HapMap populations. These two populations were selected because evidence suggests that the 
Ashkenazi population is characterized by the presence of haplotypes that are both European and 
North African in origin. The first two principal components were plotted, and the population 
clustered together, reflecting the coancestry of the study population.  
 
Plots 
The Manhattan plots and Q-Q plots were produced using the “qqman” package in the R 
software package. The plot of the association signal for LRRK2 was produced in Locus Zoom 
(32) using data from the 1000 Genomes project European population (hg19). 
 
2.3 Results 
Initial GWAS 
An initial GWAS was conducted in an Ashkenazi population from New York consisting 
of 25 LRRK2-G2019S positive individuals, 96 IPD cases, and 96 controls. Only individuals with 
4 Ashkenazi grandparents were included in the study, and the absence of population admixture 
was confirmed by genetic analysis with the Eigenstrat software package. IPD cases were 
confirmed by Dr. Susan Bressman, a movement disorder specialist, and were obtained in 
collaboration with Dr. Laurie Ozelius of the Mount Sinai School of Medicine. Family history 
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information was collected from each patient, and none of the subjects included in the analysis 
was known to be related or had a measured pair-wise kinship coefficient greater than 0.1 with 
another participant (i.e., less related than first cousins) as measured by PLINK. The samples 
were genotyped on the Affymetrix GeneChip Human Mapping 500K platform, and the 
genotypes were called with the Birdseed V2 algorithm included in the Affymetrix Genotyping 
Console Software package. SNPs were filtered based on the MAF, missingness of genotypes, 
and violation of Hardy-Weinberg equilibrium; after this, 357,319 markers remained. The 
significance of the associations was calculated by comparing the distribution of the genotypes 
between the cases and controls with Fisher’s exact test. 
An examination of the distribution of the association statistics indicated the possibility of 
Type I errors. There were far more significant associations than what would have been expected, 
which was confirmed by a Q-Q plot (Figure 2.1). The high rate of positive associations was due 
to the aggressiveness of the genotype calling algorithm. Visual analysis of the genotyping cluster 
plots allowed for the exclusion of SNPs that were not called correctly.  
By reducing the possibility of false positive associations resulting from aggressive 
genotype calling through visual genotype plot analysis, the list of loci potentially associated with 
IPD was refined. The most significantly associated SNPs are listed in Table 2.1. A significant 
association signal was not detected across LRRK2, most likely because the Affymetrix 500K 
platform does not tag this mutation well and because the signal was obscured by the cases 
without LRRK2 mutations (Figure 2.2). LRRK2 was significantly associated in this sample only 
when considering the LRRK2-positive cases vs. the controls (Figure 2.3), which illustrates why 
previous IPD GWAS have been unable to find a significant association in the region of LRRK2 
(17, 18). Of the associations that were identified, the association at rs11167267 on chromosome 
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20q11.22 was the most significant with a p-value of 9.21 X 10
-7
, which is greater than the 
threshold for genome-wide significance. This variant is located in C20ORF173. Because of the 
small sample size of this initial GWAS, a replication GWAS was performed. 
 
Replication GWAS 
For the replication phase of the study, the study group initially consisted of 166 IPD cases 
and 1,436 controls. The cases included 50 individuals that were known LRRK2 G2019S mutation 
carriers. The controls included 105 dystonia patients, 407 schizophrenia patients, 273 Crohn’s 
disease patients, and 651 healthy individuals. After filtering out individuals for relatedness, 161 
cases and 1,404 controls remained. All samples were genotyped on the Affymetrix 6.0 
genotyping platform, which allows for the genotyping of nearly one million SNPs. After filtering 
for missingness and MAF as described above, 634,338 SNPs remained. To provide greater 
coverage of the genome, imputation was performed with MaCH to infer the genotypes for 
additional markers using the HapMap CEU population. When including the imputed SNPs, the 
dataset consisted of 2,557,252 SNPs. The association statistics were calculated using the 
mach2dat tool. The p-values for the most significantly associated SNPs are listed in Table 2.2, 
and the results are displayed as a Manhattan plot in Figure 2.4.  
Two SNPs on chromosome 12 were found to have association signals with genome-wide 
significance: rs10506095 (p= 2.49x10-10) and rs7316771(p=1.19x10-9). Both are located in an 
intergenic region on chromosome 12p11.21, but these markers flanked FGD4. One SNP on 
chromosome 17q21.2 was also found to have a genome-wide significant association signal: 
rs3887424 (p=4.29x10
-8
). This SNP was located in an intronic region of ACLY. 
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Another noteworthy finding was the presence of a genome-wide suggestive association 
signal across 23 SNPs on chromosome 12q12, which included the LRRK2 locus, as well as the 
SLC2A13 and CNTN1 loci (Figure 2.5); these loci are located upstream and downstream of 
LRRK2, respectively. This finding was somewhat expected because of the inclusion of known 
LRRK2 mutation carriers in the study. The average p-value for this signal was 4.85 x 10
-6
; this 
signal most likely did not reach genome-wide significance because of the inclusion of subjects 
without known LRRK2 mutations. This finding suggests that even within this population, there is 
genetic heterogeneity in the etiology of IPD. Furthermore, these results confirm those of a 
previous GWAS of IPD performed in a Japanese population that found significant associations 
for SNPs that were upstream of LRRK2 (20).                
 
2.4 Discussion 
The results of this study provide further evidence that IPD is genetically heterogeneous. 
The inclusion of 50 known LRRK2 G2019S mutation carriers in the replication study group 
enabled the detection of an association signal across 12q12. The strong association signal 
suggests that IPD patients with a LRRK2 mutation share a distinct genetic etiology that may have 
arisen from a common ancestor. LRRK2 was also recently associated with Crohn’s disease, 
which, like IPD, is also more common in the Ashkenazi than in the general European population. 
Recent studies have found that this gene is expressed in immune cells and could participate in 
processes such as inflammation (33). In IPD, the penetrance of LRRK2 mutations is relatively 
low, which indicates that additional mutations must be identified.  Future research into this 
gene’s pathways will provide a better understanding of its role in the etiology of both IPD and 
Crohn’s disease.    
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Because the Ashekenazi population is characterized by shared coancestry, the number of 
potential haplotypes in the population was lower than would be expected, which made it more 
likely that causal variants were shared IBD from a common ancestor. Thus, future IPD GWAS 
could increase their power to detect associations, not only by increasing the number of subjects, 
but also by focusing on specific populations. 
With the advent of massively parallel sequencing (MPS) technologies, however, it is far 
more likely that future studies will focus on whole genome/exome sequencing to identify 
variants that contribute to the etiology of IPD. For the past few years, researchers have debated 
how much of the genetic variation in a disease can be explained by the common variants sought 
by GWAS. In the case of IPD, the MPS approaches can complement the findings of GWAS by 
identifying variants in known IPD susceptibility genes, such as MAPT, SNCA, and LRRK2. 
Future research should yield insight into the biological pathways that cause this disease and 
identify potential therapeutic targets.   
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Figure 2.1: Quantile-quantile plot of the observed (blue) vs. the expected (green) distribution of 
p-values for the initial IPD GWAS 
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Figure 2.2: Manhattan plot of the –log10(p-values) of the initial IPD GWAS.  
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Figure 2.3: Manhattan plot of the association signal across LRRK2 for the initial GWAS 
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Figure 2.4: Manhattan Plot of the –log10(p-values) of the replication IPD GWAS. SNPs in the 
LRRK2 region are in green. 
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Figure 2.5: Plot of the Association Signal Across the LRRK2 region 
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Table 2.1: Significant SNPS (p<1.0x10
-5
) in the initial IPD GWAS 
SNP Chromosome Position Alleles P-value Locus 
rs11167267 20 33572687 G/T 9.21E-07 LOC729591  
rs4443273 4 14417782 C/T 1.50E-06   
rs794148 4 110178444 A/C 5.78E-06 COL25A1  
rs181311 14 47408911 G/T 8.14E-06  
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Table 2.2: Significant SNPs (p<1.0x10
-5)
 in the replication IPD GWAS 
SNP Chromosome Position Alleles P-value Locus 
rs7534906 1 197798537 A/G 7.02E-06 CAC1S  
rs12409138 1 197799441 C/T 4.67E-06 CAC1S  
rs17454947 1 197801418 A/C 6.02E-06 CAC1S  
rs10520244 2 79672427 C/T 8.31E-06 CTN2  
rs10520245 2 79672517 G/T 8.13E-06 CTN2  
rs16852806 2 167632117 C/T 9.55E-06 XIRP2  
rs11889300 2 167632527 A/G 9.52E-06 XIRP2  
rs11896680 2 167633994 C/T 5.78E-06 XIRP2  
rs7578258 2 216607237 A/G 5.04E-06  
rs1724725 3 159385098 C/T 3.12E-06 RSRC1  
rs827152 3 159392089 C/T 9.44E-06 RSRC1  
rs13128422 4 17155671 C/T 6.52E-06  
rs13128864 4 17155877 C/G 6.60E-06  
rs7666115 4 189593305 C/T 4.68E-06  
rs323653 5 2693466 C/T 8.84E-06  
rs10035114 5 2702027 A/T 5.01E-06  
rs6863801 5 2702263 A/G 5.00E-06  
rs17294992 5 157459405 C/T 7.59E-06  
rs7462014 8 10944461 A/C 1.63E-06 XKR6  
rs7821584 8 10952970 G/T 1.07E-06 XKR6  
rs13261970 8 19173262 C/G 9.18E-06  
rs1193308 8 19177828 C/T 5.81E-06  
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rs1193296 8 19187657 A/G 4.50E-06  
rs1514701 8 19206223 A/G 3.44E-06  
rs1193304 8 19208810 A/G 3.74E-06  
rs10741067 10 25160382 A/G 3.36E-06  
rs11220605 11 126146741 C/T 4.00E-06 KIRREL3  
rs17563276 12 31564296 C/T 5.38E-06 MGC24039  
rs10844094 12 32065781 G/T 6.11E-07  
rs7316376 12 32070167 A/G 1.20E-06  
rs12230201 12 32074419 C/T 8.96E-06  
rs10466825 12 32075914 A/G 5.83E-06  
rs12426455 12 32077228 C/T 2.06E-06  
rs10844098 12 32078551 A/G 7.19E-07  
rs12309730 12 32079488 A/C 7.08E-07  
rs7316771 12 32117395 A/G 1.19E-09  
rs1995303 12 32539025 C/T 6.24E-08  
rs17609576 12 32565912 G/T 3.89E-06 FGD4  
rs10506095 12 32691394 A/G 2.49E-10  
rs11052837 12 33723272 G/T 1.42E-06  
rs10844685 12 33738527 A/G 1.32E-06  
rs10844691 12 33747193 A/G 1.33E-06  
rs10128817 12 33750401 A/G 1.33E-06  
rs12303803 12 33757777 A/G 1.33E-06  
rs10844695 12 33760364 C/T 1.33E-06  
rs10844696 12 33763068 C/G 1.33E-06  
rs11052866 12 33763963 C/T 1.33E-06  
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rs12303090 12 33790590 C/T 8.81E-07  
rs12304892 12 33800536 C/G 3.09E-06  
rs11052894 12 33802361 A/G 3.11E-06  
rs10844701 12 33803535 C/T 3.11E-06  
rs1917788 12 33805295 C/T 3.56E-06  
rs1917787 12 33805365 C/T 3.59E-06  
rs10844704 12 33812449 A/C 3.92E-06  
rs8181672 12 33816074 C/T 7.28E-07  
rs7358615 12 33823930 A/C 4.08E-06  
rs11052909 12 33828400 A/T 4.36E-06  
rs12372058 12 36483324  8.32E-06  
rs11181339 12 36608538 G/T 9.44E-06  
rs4520663 12 36693099  7.69E-06  
rs11181857 12 36699522 C/G 9.45E-06  
rs11181864 12 36701491  9.45E-06  
rs11174697 12 38682716 C/T 2.88E-06 SLC2A13  
rs28370649 12 38685416 A/G 2.87E-06 SLC2A13  
rs28370650 12 38686215 A/T 2.86E-06 SLC2A13  
rs28370664 12 38699572 A/C 7.69E-06 SLC2A13  
rs17442721 12 38822040 C/G 9.07E-06  
rs17483919 12 38841841 C/T 7.54E-06  
rs17465751 12 38907148 C/T 3.88E-06 LRRK2  
rs17443882 12 38993127 C/T 4.73E-06 LRRK2  
rs1866996 12 39611343 G/T 6.37E-06 CNTN1  
rs11179174 12 39633654 A/T 6.31E-06 CNTN1  
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rs1442190 12 39651907 A/G 6.43E-06 CNTN1  
rs11179263 12 39655042 A/G 6.18E-06 CNTN1  
rs278914 12 39670040 G/T 5.15E-06 CNTN1  
rs12296475 12 39674979 A/G 3.13E-06 CNTN1  
rs9652040 12 39679144 C/G 3.14E-06 CNTN1  
rs278903 12 39686710 C/T 4.88E-06 CNTN1  
rs278902 12 39687471 A/G 3.14E-06 CNTN1  
rs278901 12 39688545 A/G 3.15E-06 CNTN1  
rs280355 12 39690372 C/T 3.14E-06 CNTN1  
rs157126 12 39692596 A/G 2.93E-06 CNTN1  
rs397967 12 39694401 A/G 4.79E-06 CNTN1  
rs278900 12 39695078 A/T 4.27E-06 CNTN1  
rs280357 12 39698403 C/T 6.50E-06 CNTN1  
rs280361 12 39699334 C/T 5.01E-06 CNTN1  
rs280362 12 39700624 A/C 5.23E-06 CNTN1  
rs11169141 12 48432726 A/G 3.17E-07 TEGT  
rs9548650 13 38640007 A/C 5.81E-06  
rs1775671 14 86373673 A/G 6.45E-06  
rs8016073 14 94095240 C/T 7.48E-06  
rs910353 14 94098498 A/G 7.66E-06 SERPI4  
rs2284655 14 94101183 A/G 8.07E-06 SERPI4  
rs4905223 14 94106776 A/G 2.73E-06  
rs1998243 14 94107549 C/G 2.04E-06  
rs761536 14 94109674 C/T 2.02E-06  
rs1955652 14 94111231 A/G 2.02E-06  
 50 
 
rs8022491 14 94114330 A/G 2.07E-06  
rs1983657 14 94117046 A/T 2.12E-06 SERPI5  
rs4392030 15 24573424 C/G 6.16E-06  
rs7182514 15 24575314 A/G 6.25E-06  
rs7165224 15 24575429 C/T 6.28E-06  
rs9324132 15 24579670 C/G 8.01E-06  
rs7174912 15 24579934 C/G 9.11E-06  
rs7170353 15 24582371 C/T 6.74E-07  
rs7497827 15 24584497 G/T 7.77E-06  
rs11161340 15 24584610 A/G 9.88E-06  
rs7495536 15 24584887 G/T 9.87E-06  
rs7183073 15 24585118 G/T 7.05E-06  
rs4906904 15 24585178 A/G 7.00E-06  
rs4906905 15 24585338 A/T 6.99E-06  
rs4906906 15 24585616 A/C 5.84E-07  
rs8028779 15 24585824 C/T 6.95E-06  
rs4632102 15 24586127 C/T 6.81E-06  
rs6576616 15 24586375 A/G 9.41E-06  
rs6576617 15 24586468 A/G 9.39E-06  
rs7495131 15 24587031 A/G 9.26E-06  
rs7170111 15 24587839 A/G 9.29E-06  
rs6576619 15 24597498 A/T 5.86E-06  
rs4889373 16 80305103 A/G 8.74E-06  
rs3887424 17 37279744 C/T 4.29E-08 ACLY  
rs9897679 17 49236622 C/T 5.69E-06  
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rs6047628 20 21722338 C/G 9.53E-06  
rs13057533 22 28935285 C/T 5.42E-06 LOC729980  
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Chapter 3 
A Pilot GWAS of Idiopathic Focal Dystonia identifies an Association Signal at RNF213 
3.1 Introduction 
The genetics of dystonia, a group of neurological disorders in which the muscles contract 
involuntarily, are still largely unexplained. The disease is characterized by considerable clinical 
heterogeneity. There are both early onset and late onset forms of the disease. Furthermore, the 
disease can be classified as being generalized or focal; focal dystonias can affect muscles near 
the extremities, eyes, and vocal cords, among others. The extent to which this disease is heritable 
is unclear. There is currently no cure for dystonia, and treatment is only available to remediate it 
symptoms; thus, establishing an understanding of the genetic causes of dystonia is crucial for 
identifying the pathways involved in this disease and potential therapeutic targets. 
To date, family-based linkage studies have identified a number of loci as being 
implicated in this disease, especially in primary dystonia. The majority of early-onset, 
generalized dystonias are believed to share a common genetic etiology. The first of these linked 
genes, TOR1A, which is also known as DYT1, was mapped to chromosome 9q34; this gene 
encodes a protein known as torsinA (1). A three base-pair deletion, known as the GAG deletion, 
within this gene was shown to be responsible for the majority of primary, early-onset torsion 
dystonias and was identified as having an autosomal dominant mode of inheritance
 
(2).  
However, this gene was also found to be linked to focal dystonias (3,4). Furthermore, the TOR1A 
deletion was estimated to have between 30% and 40% penetrance (5-8).  
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In idiopathic focal dystonias, there is emerging evidence for a genetic etiology
 
(9); 
however, no genes have been implicated in this disease. There is no clear estimate of the 
heritability of focal dystonias in families, and the disease can also occur sporadically.  Because 
the likelihood of an affected individual having a family member with the disease is estimated to 
be approximately 20% (10), it is possible that any causative variants are characterized by low 
penetrance. This suspected low penetrance, coupled with the uncertain heritability of the 
condition, makes it difficult to investigate the genetics of this disease through family studies.  
To better understand the genetics of focal dystonias, we instead sought to identify the role 
of common genetic variants. Thus, we aimed to perform the first GWAS of dystonia.  
The study was performed in an Ashkenazi Jewish population from New York. The 
prevalence of primary dystonia is estimated to be 152 per 1,000,000 in the European population, 
and the prevalence of blepharospasm, a focal dystonia that causes uncontrolled contractions of 
the eyelids, is estimated to be 36 per 1,000,000 (11). However, because dystonia is believed to be 
5-10 times more prevalent in the Ashkenazi than in the overall European population (8, 12), 
sample recruitment was easier.  
Another advantage of examining the genetics of dystonia within this population is that 
the shared genetic background of the Ashkenazi increased the possibility of finding a shared 
genetic etiology that originated through a founder’s effect. The number of haplotypes present in 
the Ashkenazi population is lower than what would be expected due to inbreeding and genetic 
drift. Furthermore, the Ashkenazi genetic background is comprised of both European and 
African haplotypes (13), which increases the likelihood that the results of the study will be 
generalizable. It has already been shown that the GAG deletion in TOR1A is linked to dystonia in 
both Ashkenazi and non-Jewish cases, so it is possible that any variants associated with focal 
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dystonia will be relevant in several populations. Thus, by electing to perform the GWAS within 
the Ashkenazi population, we increased our power to detect an association. 
The study identified two SNPs on chromosome 17q25.3 with genome-wide significance: 
rs12601730 (p=2.40x10
-9
, OR = 2.169) and rs12603583 (p=2.61x10
-9
, OR=1.942).  These 
markers were in strong LD with each other (r
2
=0.87) Imputation to infer genotypes identified 
two more markers with genome-wide significant association signals that were in strong linkage 
disequilibrium with the two genotyped markers rs4889968 (p=2.61 x 10
-9
) and rs9902013 
(p=3.84 x10
-9
).  All of these markers were located within an intronic region of RNF213, which 
encodes a protein of unknown function with a RING finger domain and a Walker domain. 
These findings provide evidence for a genetic etiology for focal dystonias and formulate insights 
for future research to describe the cause of this disease.  
 
3.2 Methods 
Sample recruitment 
The samples were recruited in New York, New York and evaluated by Dr. Bressman, a 
movement disorder specialist, according to current clinical criteria. Only individuals who had 
four Ashkenazi grandparents were included in the study. The majority of cases were diagnosed 
with primary, idiopathic blepharospasm, and the rest were diagnosed with other focal dystonias. 
The controls were either healthy individuals or individuals who had been diagnosed with either 
idiopathic Parkinson’s disease, Crohn’s disease or schizophrenia.  
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Genotyping 
All samples were genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0 
platform according to the manufacturer’s protocol, and the genotype calls were made using the 
Birdseed V2 algorithm included in the Affymetrix Genotyping Console Software package. 
 
Quality control of SNP Genotyping 
Standard quality control measures were used to filter the genotyping calls with the 
PLINK software (14). Only SNPs with a minor allele frequencies > 0.05 and genotyping rates > 
90% that did not violate Hardy-Weinberg equilibrium were included in the association analysis.  
After removing these SNPs, 634,338 markers remained. 
To prevent type I error that resulted from aggressive genotyping calling by the Birdseed 
algorithm, we plotted the fluorescent probe intensities for each allele for each genotype for SNPs 
with p-values that were less than 1.0 x 10
-5
. These scatter plots allowed us to determine if the 
genotype calls had been made inappropriately. 
 
Analysis of Population Stratification 
Population stratification is known to confound the results of association studies. To 
assess population stratification, the genomic control inflation factor,, was calculated using the 
EIGENSTRAT software suite (15) by selecting a subset of SNPs that were in linkage 
dysequilibrium with each other. The median of the observed Chi-square distribution of the 
association values for these SNPs was divided by the expected median of this distribution to 
obtain a value of 1.04, which was indicative of negligible population stratification. 
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To further rule out population stratification, principal components analysis was 
performed in EIGENSTRAT by comparing the study population with the CEU and YRI HapMap 
populations. The two principal components were plotted, and our population clustered together, 
reflecting the homogeneity of the study population.  
 
Power Calculations 
The QUANTO software was used to calculate the power of the study, assuming an 
additive model and a binary outcome. The number of cases needed to achieve 80% power to 
detect an association for a case:control ratio of 1:14 was computed for minor allele frequencies 
from 0.05 to 0.50 at increments of 0.025. 
 
Association Analysis 
The association analysis was performed with the mach2dat tool, associated with the 
MACH (Markov Chain Haplotyping) software package (16, 17). An association was considered 
to have genome-wide significance if the p-value was less than 2.0 x 10
-8
; this threshold was 
determined using Bonferroni’s correction (p ~ 0.05/2,500,000 markers).  
 
Imputation 
Additional genotypes were imputed using MACH. A set of reference haplotypes was 
created using the HapMap2 CEU population after first ensuring that the alleles from our study 
matched the HapMap alleles for SNPs that were found in both data sets (i.e., that they were 
genotyped on the same strand). The genotypes from the HapMap data were phased to produce a 
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set of reference haplotypes with the following parameters:  --rounds 20, --states 300, --phase, --
interim 5, --sample 5, --compact. 
Then, this set of reference haplotypes was used to impute additional markers in our study 
data with the following options in MACH: --rounds 5, --states 200. For genotype inference, only 
SNPs genotyped on the Affymetrix platform with genotyping rates > 90% and minor allele 
frequencies > 5% that did not violate Hardy-Weinberg equilibrium (p< 0.000001) were included 
in the input files.  
 
Plots 
The Manhattan plot and Q-Q plot were produced using “qqman” in the R software 
environment. The plot of the association signal and linkage disequilibrium for RNF213 was 
produced in Locus Zoom (18) using data from the 1000 Genomes project European population 
(hg19). 
 
3.3 Results 
The sample consisted of 105 cases that had been diagnosed with focal dystonias (mostly 
blepharospasm) and 1495 controls from the Ashkenazi population. We included individuals with 
focal dystonias other than blepharospasm because there is evidence that all focal dystonias share 
a genetic etiology (19).  The controls were comprised of both healthy individuals and individuals 
who were diagnosed with unrelated diseases (Crohn’s disease, idiopathic Parkinson’s disease, 
and schizophrenia).  Because of the small sample size, the study was expected to have sufficient 
power to identify associations with odds ratios that were comparatively higher than those found 
by most recent association studies. Power calculations indicated that the study had 80% power to 
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detect associations with odds ratios between 1.75 and 2.10, depending on the minor allele 
frequency.  
After genotyping the samples on the Affymetrix Genome-Wide Human SNP Array 6.0 
platform, both the subjects and markers were checked for missingness of genotypes. Three 
subjects, all controls, were excluded for having a genotyping rate less than 90%; the average 
genotyping rate was 96.1%. Markers were excluded using PLINK on the basis of low genotyping 
rates (genotyping rate <90%, 55,310 SNPs), low minor allele frequencies (MAF<0.05, 227,747 
SNPS) and violating Hardy-Weinberg equilibrium (195,09 SNPS).  After these steps, 634,338 
autosomal SNPs were analyzed. To rule out the possibility of improper genotype calling by the 
Birdseed V2 algorithm, the genotype clustering plots of the Affymetrix probe intensities were 
visually inspected for all SNPs with p < 1.0 x 10
-5
. This step was necessary because the Birdseed 
algorithm will frequently assign genotypes to samples when the fluorescent probe intensity is 
low; thus, we needed to check that this aggressive genotype calling had not occurred. Any SNPs 
for which it appeared that the majority of genotypes had been called incorrectly were removed 
from further analysis.  
The case-control analysis revealed 2 SNPs on chromosome 17q25.3, rs12601730 
(p=2.40x10
-9
, OR = 2.169) and rs12603583 (p=2.61x10
-9
, OR=1.942), that had association 
signals with genome-wide significance (p < 2.0 x 10
-8
), as indicated by the Manhattan plot in 
Figure 3.1. These two markers were in strong linkage disequilibrium with each other (r
2
=0.87).  
Both SNPs were located in an intronic region in RNF213. This gene encodes a RING finger 
protein of unknown function.  
The Q-Q plot (Figure 3.2) of the association p-values indicates that the observed 
distribution of p-values only deviated slightly from the expected distribution of p-values. This 
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deviation largely occurred in the right tail end of the distribution, suggesting that there was 
negligible Type I error in the association analysis. The genomic control inflation factor, λ, was 
calculated as 1.04, which suggests that the results were not influenced by population 
substructure. Population substructure was further ruled out by performing principal components 
analysis in EIGENSTRAT with the European and African populations from HapMap II.  The 
plot of the first two principal components was indicative of strong homogeneity within the study 
population (data not shown). 
After performing the initial analysis, additional markers were imputed using MACH 
(MArkov Chain Haplotyping) for a total of 2,500,000 genotyped SNPs. To ensure that markers 
were not inappropriately excluded we checked for compatibility between the alleles in the 
HapMap data and the Affymetrix data.  Two more markers were found to have associations with 
genome-wide significance: rs4889968 (p=2.61 x 10
-9
) and rs9902013 (p=3.84 x10
-9
).  These 
SNPs were in the same LD block with the other two significant SNPs on chromosome 17q25.3 
(Figure 3.3).  Thus, we identified a strong association between RNF213 and dystonia. Below we 
posit the role that mutations within this gene could play. 
 
3.4 Discussion 
We performed the first genome-wide association study of idiopathic dystonia and found 
an association signal with genome-wide significance at chromosome 17q25.3. This association 
signal was located within an intronic region of RNF213, which encodes a RING (Really 
Interesting New Gene) finger protein. While these variants were found within an intronic region, 
it is possible that they are in LD with rare variants that could disrupt the protein-coding region of 
this gene. RING finger domains are stable structures between 40 and 60 amino acids that are able 
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to bind 2 zinc cations. More importantly, RING finger proteins can participate in ubiquitination 
by acting as E3 ubiquitin ligases. The disruption of ubiquitination, which could prevent proteins 
from being targeted for degradation, has been shown to play a role in a number of neurological 
disorders, such as Parkinson’s disease and Alzheimer’s disease. Recent research has suggested 
that mutations in TOR1A, the gene implicated in primary, early-onset torsion dystonia, disrupt 
ubiquitin-mediated protein degradation and lead to the formation of protein aggregates within the 
brain. Thus, mutations in RNF213 could act similarly by disrupting ubiquitination and preventing 
appropriate protein degradation. 
The RNF213 protein also contains a Walker motif, which could confer ATP-binding 
activity. Interestingly, TOR1A codes for a protein that also contains an ATP-binding domain. The 
causative GAG-deletion is believed to act by disrupting the ATP-binding activity of the protein.   
RNF213 was recently implicated in the first genome-wide association study of 
Moyamoya disease (MMD) in a Japanese population (20). In patients with MMD, blood vessels 
in the brain are blocked, causing the formation of auxiliary blood vessels that are weak and prone 
to hemorrhage. In this particular GWAS, the researchers found an association signal with 
genome-wide significance for a 7-SNP haplotype that was not in LD with the SNPs implicated in 
this study. In forwarding the functional characterization of the protein, these researchers 
performed a preliminary analysis of mRNA and protein expression in several tissues through 
RT-PCR and Western blotting, respectively.  RNF213 mRNA was highly expressed in the 
skeletal muscle and the cerebellum, but not in the whole brain.  This expression in the 
cerebellum is of interest because the latest models of dystonia suggest involvement of both the 
cerebellum and basal ganglia. 
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At first glance, it would appear that dystonia and MMD are largely unrelated. However, 
models for both diseases implicate the basal ganglia. Interestingly, there have been a few cases 
of MMD patients developing secondary movement disorders, including dystonia (21). MMD 
patients presenting with secondary dystonia were shown to have lesions in the basal ganglia. 
Thus, mutations in RNF213 may play a role in both conditions.  
More research is needed to characterize the expression of RNF213 and to verify its role in 
dystonia. A better understanding of this gene will lead to a better understanding of the pathways 
and regions of the brain involved in this disease. 
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Figure 3.1: Manhattan plot of the –log10(p-values) of the dystonia GWAS. 
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Figure 3.2: Quantile-quantile plot of the observed vs. the expected distribution of p-values for the 
dystonia GWAS.
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Figure 3.3: Plot of the association signal across RNF213. The imputed SNPs are marked as a 
square, while the genotyped SNPs are marked with a circle. The SNP with the most significant 
association signal (rs12601730) is displayed in purple. 
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Chapter 4 
Combined Exome and Whole Genome Sequence Analysis of FTD-ALS family San Francisco-A 
 
4.1 Introduction  
Recent research strongly suggests that amyotrophic lateral sclerosis (ALS), a 
neurodegenerative disease characterized by progressive motor neuron loss (1), and 
frontotemporal dementia (FTD), the second leading cause of pre-senile dementia after 
Alzheimer’s disease (2), are different manifestations of the same genetic cause. Approximately 
15% of FTD patients will also have amyotrophy (3), and many patients that present with 
amyotrophy have loss of frontal lobe cortical neurons in the distribution typical of FTD (4). 
The ALS-FTD disease spectrum is genetically heterogeneous. A common cause of 
familial and sporadic cases of FTD-ALS that segregates with chromosome 9p21.2 is a 
hexanucleotide repeat (GGGGCC) expansion in the noncoding region of the uncharacterized 
gene C9orf72 (5-7). The transcribed product of this expanded repeat has been found in the nuclei 
of affected individuals; the transcript is translated into an aggregated dipeptide repeat protein (8). 
The loci responsible for a substantial portion of familial FTD cases are linked to 17q21 and can 
be attributed to mutations of the microtubule-associated protein tau gene (MAPT) (9) or 
progranulin gene (GRN) (10). A few patients with MAPT mutations present with amyotrophy, 
but most present with FTD (11). FTD-ALS, however, is typically not characterized by tau 
inclusions; the pathology is instead classified as ubiquitin-positive (12). There are other 
mutations known to cause autosomal dominant FTD and/or ALS, such as those in TARDBP (13), 
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ATXN2 (14), VCP (15), CHMP2B (16), FUS (17), DCTN1 (18), SOD1 (19), ANG (20), and 
VAPB (21). 
Our study addresses the genetics of FTD-ALS in a family, henceforth called San-
Francisco A (SF-A), with an atypical pathology. Previously, an autopsy of one family member 
revealed both tau and alpha-synuclein inclusions (12). While FTD is regularly characterized by 
tau inclusions, the ubiquitin-positive inclusions in ALS patients can be comprised by SOD1, 
TDP-43, or FUS. At the time of this report, there was no tissue available for family SF-A for re-
evaluation of the presence of these inclusion proteins.  
The unique pathology observed in family SF-A suggests that the genetic etiology of 
FTD-ALS is also unique in this family. Microsatellite data had yielded a linkage signal on 
chromosome 17q (12). However, the MAPT locus was not within the support interval. 
Furthermore, resequencing of the MAPT exons in 3 affected individuals in SF-A did not discover 
any novel or known sequence changes, suggesting that the tau inclusions may not have been 
caused by mutations in the tau gene. Therefore, additional studies were needed to identify the 
mutation responsible for the disease in family SF-A.  
To this end, the current study performed whole exome sequencing (WES) of ten family 
members and whole genome sequencing (WGS) of one affected family member with the hope of 
discerning the genetic etiology of this form of FTD-ALS. By first sequencing the exons of the 
entire genome using massively parallel sequencing (MPS) technology, this study sought to 
identify the causative mutation responsible for the disease in SF-A. While it is possible to 
sequence the entire genome, 85% of the mutations that explain diseases with simple modes of 
inheritance are in coding sequences, which comprise approximately 1% of the genome (22-23). 
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WGS of one subject was pursued in addition to WES to identify potentially interesting variants 
outside of the coding regions.  
After submitting the samples for MPS, a family informant interviewed ten years after the 
last assessment indicated that two individuals, who were previously believed to be affected, that 
had substantial behavioral problems had not progressed over several years and have now been 
lost to clinical follow-up.  
In this study, WES and WGS failed to detect a rare splice junction, missense or nonsense 
mutation in the affected family members for any genes on 17q, known genes that cause FTD 
and/or ALS, and the entire exome. Furthermore, repeat-primed PCR did not detect the presence 
of the C9orf72 hexanucleotide repeat expansion. Multipoint linkage analysis with 163,082 
polymorphisms detected by WES now excludes 17q; with the updated phenotype data, a linkage 
signal on chromosome 9q32-34 that segregated with the disease (LOD=1.8) was identified. 
While this LOD score was below the threshold conventionally used to prove linkage, the rest of 
the genome was exluded. In the potentially linked region on chromosome 9q, a mutation not 
detected in thousands of genomes was shared by all the affected individuals in CRB2; the protein 
encoded by this gene has been shown to bind presenilin and suppress the activity of the gamma-
secretase complex. While the c.C3459T mutation is synonymous, it may affect gene expression. 
Furthermore, WGS of one affected individual to identify additional variants of interest in regions 
beyond the targeted exome identified a 27-bp deletion (g.61699_61725del27) in LAMC3, a gene 
involved in the development of the cerebral cortex. Thus, WGS and WES failed to identify a 
likely causal mutation, which suggests that the mutation responsible for FTD-ALS in family SF-
A could not be detected by the MPS approaches used in this study.  
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4.2 Methods 
Subjects 
The pedigree investigated in this study had been previously characterized by Wilhelmsen 
et al. (12). Recently, a family representative and the spouses of several family members that have 
died in the interval were interviewed. All but two of the previously identified affected family 
members progressed and died of FTD/ALS. Two family members (listed as III-1 and III-7 in the 
pedigree in Figure 4.1) with behavioral disturbances reportedly did not progress over several 
years and have been lost to follow-up. One of these individuals is now believed to have had 
longstanding behavioral disturbances that were possibly due to viral encephalitis. DNA was 
extracted from whole blood samples for 10 family members using a DNA isolation kit 
(Puregene; Gentra Systems Inc, Minneapolis, MN).  
 
C9orf72 Locus Genotyping 
DNA from ND07489 was obtained from Corielle to act as a positive control. Repeat-
primed PCR was performed largely as described in Renton et al. and Dejesus-Hernandez et al. 
(5-6). The PCR fragment lengths were analyzed with an ABI 3730xl genetic analyzer and the 
Peak Scanner software.  
 
Massively Parallel Sequencing 
For the WES, genomic DNA samples from ten subjects (see Figure 4.1) were selectively 
enriched for exomic DNA using the SureSelect Human All Exon 50 Mb kit (Agilent, Santa 
Clara, CA). Illumina Hiseq2000 adapter sequences (Illumina, San Diego, CA) were ligated to the 
DNA fragments. Library preparation was then conducted according to the manufacturer’s 
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instructions. Next, 76-bp paired end reads were generated with the Illumina HiSeq2000 platform 
and CASAVA v1.8 pipeline. 
For the WGS, genomic DNA for one affected subject (listed as II-6 in Figure 4.1) was 
submitted to massively parallel sequencing on the Illumina HiSeq 2500 platform after library 
preparation, and 100-bp paired end reads were generated. 
The reads were aligned to the reference genome (hg19) using the Burrows-Wheeler 
aligner (BWA) (24). The resulting SAM (Sequence Alignment/Map) file was sorted using 
SAMtools and converted to a BAM (binary SAM) file (25). Duplicate reads were removed using 
Picard (26). The resulting BAM files were processed with the GATK pipeline v.2.0 for multi-
sample variant detection (27). To improve the quality of genotype calls, the genotypes for the 10 
exomes were called in concert with the genotypes from a set of 100 exomes from unaffected 
individuals of European descent using the GATK Unified Genotyper (28). The variants were 
annotated using the SeattleSeq 134 pipeline and the pipeline constructed by the bioinformatics 
group at the Renaissance Computing Institute (RENCI, www.renci.org) directed by KCW that 
was constructed for the University of North Carolina at Chapel Hill NHGRI-funded NCGENES 
project, which is assessing the utility of WES in medical genetics.  
 
Linkage Analysis 
To create the marker set (163,082 single nucleotides polymorphisms) used for linkage 
analysis, the PLINK software was used to identify markers in linkage equilibrium from WES 
data for 100 individuals of European descent (29). Markers were further excluded for having a 
minor allele frequency less than 5%.  
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The Merlin software was used to confirm the expected relationship between family 
members (30). Next, Merlin’s genotype error detection algorithms were used to examine 
genotype data, blind to phenotype data, to identify and exclude rare markers inconsistent with 
Mendelian segregation. Multipoint linkage analysis was performed in Merlin, assuming an 
autosomal dominant pattern of inheritance with complete penetrance. This pattern of inheritance 
was plausible because individuals from all generations were affected, and there was male-to-
male transmission of the disease. The frequency of the potential disease-conferring allele was set 
to 0.001. For the genetic map files, the genetic distances were derived from the Rutgers Map 
Project (31).  
 
Haplotype Analysis 
Haplotype analysis of chromosome 17q was performed using the fastIBD function in 
Beagle with unphased data (32). 
 
Causal Variant Determination 
After performing the multipoint linkage analysis, variants with a minor allele frequency 
greater than 5% in dbSNP or 1000 Genomes data were excluded from further analysis. Variants 
that were present in the four affected individuals, but not in any of the unaffected individuals, 
were considered candidates. Variants were stratified based on whether they were expected to 
change the primary amino acid sequence or affect splicing.  
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RNA Secondary Structure Analysis 
The secondary structure of the mRNA for CRB2 was investigated using the RNA folding 
form application on the mFold web server at http://mfold.rna.albany.edu/?q=mfold/RNA-
Folding-Form (33). 
 
Exonic Splicing Regulatory Element Analysis 
The wildtype sequence and the sequence with the point mutation in exon 11 of CRB2 
were submitted to the ESRsearch tool at http://esrsearch.tau.ac.il/ (34). 
 
4.3 Results 
The exomes of ten individuals from family SF-A were analyzed with targeted capture and 
sequencing (Figure 4.1). A previous study of this family had indicated the presence of linkage on 
chromosome 17q21, which was distal to MAPT, and an autopsy of the brain of an affected family 
member indicated the presence of both tau and alpha-synuclein inclusions. However, 
resequencing of the MAPT exons in 3 affected individuals in SF-A did not discover any novel or 
known sequence changes, suggesting that the tau inclusions may not have been caused by 
mutations in the tau gene. Ten years after this initial study, follow-up with a family informant 
indicated that two individuals who were believed to be affected in this pedigree had not 
progressed over several years and were lost to follow-up (listed as III-1 and III-7 in the pedigree 
in Figure 4.1). The informant reported that one of the previously affected individuals with an 
unspecified behavioral disorder had episodes of what was diagnosed as viral encephalitis during 
adolescence and again as a young adult. The other patient lost to follow-up had a long history of 
adult onset behavioral problems. This change in diagnostic status for these two individuals 
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prompted a review of the previously performed linkage analysis. For the purpose the current 
study, these two individuals were classified as unaffected.  
Thus, a genome-wide linkage analysis was performed with SNP genotypes taken from 
the WES data assuming an autosomal dominant mode of inheritance. The present multipoint 
linkage excluded the 17q region, as the LOD scores across the region were negative. However, 
because of the importance of MAPT mutations in neurodegenerative diseases and the discovery 
of tau inclusions in the brain during an autopsy of a deceased family member in SF-A, variants in 
or near MAPT were investigated. Variants were selected that were present in the genomes of the 
4 affected individuals, but not the 4 unaffected individuals. In doing so, a rare, non-synonymous 
mutation was detected in LRRC37A2, which is approximately ~300 kb distal from MAPT. A 
haplotype analysis performed with Beagle, however, indicated that the haplotypes in this region 
did not segregate with disease. 
After excluding the rest of the genome by linkage analysis, a multipoint linkage signal 
was found in a 20.2 cM region on chromosome 9q32-34 (LOD=1.8) (Figure 4.2). While a LOD 
score of 1.8 is below the threshold conventionally used to prove linkage, this was the maximum 
possible LOD score in this family. No LOD scores above 1.0 were detected in any other region 
in the genome. The region is consistent with linkage and is presently the most likely region to 
harbor the mutation responsible for disease in SF-A. The discrepancy in the findings from the 
current study and the previous one can be explained by the change in the diagnostic status of two 
individuals between the previous report and the current one and by the extreme density of marker 
data in the current study, which allowed for greater confidence in concluding that the affected 
individuals shared specific haplotypes.  
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Interesting variants in the linked region were sought by looking for rare variants or 
mutations that were shared among the genomes of the affected individuals and missing from 
those of the unaffected individuals. Rare variants were defined as variants that were either not 
present in dbSNP, the 1000 Genomes data, or the EVS or that had a minor allele frequency less 
than 5%. In the linked region, one such variant was found, a single nucleotide variant in exon 11 
of Crumbs Homolog 2 (CRB2, c.C3459T).  
The mutation in Crumbs is not listed in the NHLBI Exome Sequencing Project Exome 
Variant Server (EVS). Crumbs is an intriguing candidate because of its role in Notch signaling 
and processing the amyloid precursor protein (APP). If the synonymous c.C3459T mutation in 
CRB2 is the causal variant in SF-A, this mutation may affect gene expression, e.g., by altering 
the stability of the mRNA secondary structure. The most stable secondary structure of the 
primary CRB2 transcript with c.C3459T is 5.01% less stable in terms of its folding free energy 
(G=-43.6) than the predicted structure of the wildtype transcript (G=-45.9). Another 
possibility is that this synonymous mutation could disrupt an exonic splicing enhancer (ESE) or 
introduce an exonic splicing silencer (ESS). A search for putative ESE and ESS motifs in the 
region revealed that the variant introduced a putative ESS (TGGTTCTC) 
34
. An ESS could 
contribute to alternative mRNA splicing (35).  
Because the LOD score for chromosome 9q was below the conventional threshold needed 
to prove linkage, the entire exome was interrogated for variants of interest that segregated with 
the disease, but no additional variants of interest were detected. It is also likely that the causative 
mutation for FTD-ALS in family SF-A is simply not located in the exomic regions that were 
sequenced. The hexanucleotide repeat expansion in the intronic region of C9orf72 is an example 
of a mutation that causes many familial and sporadic cases of FTD-ALS. The region containing 
 76 
 
this locus did not segregate with the disease (Figure 4.2), which suggested that this locus was not 
implicated in family SF-A. Repeat-primed PCR revealed that this family did not carry the 
C9orf72 repeat expansion (Figure 4.3). Repeat-primed PCR was carried out for all 10 family 
members that were submitted to exome sequencing. The plots of the fluorescence peaks for the 
PCR fragments indicated the presence of fewer than 30 GGGGCC repeats in this region for all 
family members, which is considered normal.  
To investigate the possibility that the causative variant occurred outside of the exome, the 
entire genome of one affected subject (II-6) was sequenced. The WGS data confirmed the 
previously detected CRB2 mutation and also detected a 27-bp deletion(g.61699_61725del27)  in 
an intronic region of LAMC3. These findings are summarized in Table 4.1. The MAF of this 
variant is not available in dbSNP, 1000 Genomes, or the EVS. The protein encoded by LAMC3, 
laminin subunit gamma-3, is expressed in the brain and plays a role in shaping the cerebral 
cortex. 
In summary, a multipoint linkage signal (LOD=1.8) was detected on chromosome 9q32-
34 for FTD-ALS with tau and alpha-synuclein aggregates in family San Francisco-A. In the 
affected individuals, this region contained a rare variant in CRB2, a gene in the gamma-secretase 
pathway.  
 
4.4 Discussion 
In the current study, a novel locus on chromosome 9q32-34 segregated with a familial 
form of FTD-ALS. While several studies have linked chromosome 9p to the disease, only one 
other study has observed linkage with chromosome 9q (36). In particular, several studies have 
cited a hexanucleotide repeat expansion in C9orf72 (9p21.2) as being implicated in both familial 
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and sporadic forms of the disease. However, the C9orf72 region failed to segregate with the 
disease and was not detected by repeat-primed PCR in this family. These findings underscore the 
genetic heterogeneity of the FTD-ALS disease spectrum. 
This study also illustrates the advantages and limitations of WES in the study of 
Mendelian diseases. WES data did provide greater resolution for performing genome-wide 
linkage analysis, but this approach failed to identify a potentially causative splice, nonsense, or 
missense mutation. Thus, it is likely that the causative mutation was not located within the 
exomes of the affected family members.  
While the rare variant in Crumbs homolog 2 (CRB2) discovered in the affected subjects 
in SF-A was synonymous, this variant could help explain the pathology of FTD-ALS. In 
humans, CRB2 inhibits the cleavage activity of the gamma-secretase complex; this protease 
complex is responsible for the cleavage of the transmembrane domains of proteins including 
APP and various Notch receptors. A study by Mitsuishi et al. found that CRB2 binds presenilin, 
one of the four main components of the gamma-secretase complex (37), and inhibits the cleavage 
of APP. APP is cleaved by the gamma-secretase complex into amyloid-beta, which is the 
primary component of amyloid plaques found in the brains of Alzheimer’s patients. Knockdown 
of endogenous CRB2 led to an increase in gamma-secretase cleavage activity (37). In 
Drosophila, the Crumbs protein has been shown to attenuate Notch-mediated transcriptional 
activation by preventing the cleavage of the Notch receptor by the gamma-secretase complex 
(38).  
Thus, this synonymous mutation in CRB2 could, via the gamma-secretase complex, affect 
the cleavage of APP and the Notch receptor. While the role of amyloid-beta in Alzheimer’s 
disease has been thoroughly investigated, more recently, Notch has also been implicated in 
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neurodegenerative pathways. Specifically, Notch-1 signaling has been shown to suppress the 
formation of new motor neurons in zebrafish (39), and the loss of motor neurons is a hallmark of 
ALS. Furthermore, TDP-43, which is now believed to be the primary component of ubiquitin 
inclusions in the brains of patients with FTD-ALS, has been shown to upregulate several Notch 
target genes in Drosophila (40). If the mutation in CRB2 found in this study modifies protein 
function and prevents CRB2 from suppressing gamma-secretase cleavage activity, this mutation 
could lead to a deregulation of Notch signaling and the subsequent loss of motor neurons.  
The 27-bp deletion detected by WGS in an intronic region of LAMC3 is interesting 
because of the role that this gene plays in the development of the cerebral cortex (41). However, 
it is unclear whether this variant affects the expression or amino acid sequence of this gene. A 
functional characterization of the detected mutation could determine whether this variant 
contributes to the etiology of FTD-ALS in family SF-A. 
Thus, a likely causative mutation was not found by either WES or WGS. The ability to 
genotype rare variants did lead to the identification of potentially interesting variants in CRB2 
and LAMC3; however, these variants will need to be characterized to determine whether they 
contribute to the phenotype in family SF-A. Current MPS strategies are limited in their ability to 
detect repeat expansions, which have been shown to play a role in neurodegenerative conditions. 
In the future, it would be prudent to investigate whether a repeat expansion could explain the 
genetic etiology of FTD-ALS in family SF-A.  
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Figure 4.1: Pedigree affected with FTD-ALS. Subjects labeled with a “+” were analyzed with 
exome sequencing. The diagnostic status of subjects III:1 and III:7 had changed since the 
previous study; both of these subjects were previously believed to be affected but have had no 
progression since the last report. Therefore, they are now considered to be unaffected. 
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Figure 4.2: Multipoint LOD scores across chromosome 9 for FTD-ALS family San Francisco-A. 
A LOD score of 1.8, assuming an autosomal dominant mode of inheritance, was seen across a 20 
cM region of 9q32-34. While this LOD score is below the threshold conventionally required to 
prove linkage, the rest of the genome was excluded.  
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Figure 4.3: Repeat-Primed PCR of the C9orf72 hexanucleotide repeat. The x-axes correspond to 
the size of the PCR products in base pairs, and the y-axes correspond to the fluorescence units. 
The sawtooth pattern of declining peaks extending past 300 bp indicates the presence of the 
repeat expansion for the positive control. The height of the peaks for the subjects from SF-A 
indicates that the alleles for these subjects feature fewer than 30 GGGGCC repeats, which is 
considered normal. 
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Table 4.1: Variants of Interest on Chromosome 9 in FTD-ALS family San Francisco-A 
Locus Variant Location Present? Evidence 
C9orf72 Hexanucleotide 
(GGGGCC)expansion 
Intronic/Promoter 
Region 
No Repeat-primed 
PCR 
CRB2 c.C3459T Exonic Yes Whole Exome 
Sequencing 
LAMC3 g.61699_61725del27 Intronic Yes Whole Genome 
Sequencing 
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Chapter 5 
 
Whole Genome and Whole Exome Sequence Analysis of a Family Affected by a Microcoria 
Myopathy 
 
5.1 Introduction 
Muscular dystrophies are characterized by significant genetic and clinical heterogeneity. 
Nicholl described a British family with members affected by a dominantly inherited proximal 
myopathy with tubular aggregates, manifesting as chronic progressive muscle weakness and 
microcoria (pin-point pupils) (1). Congential microcoria, also known as congenital miosis 
(MCOR, OMIM 156600), is a rare disease characterized by hypoplasia of the dilator pupillae 
muscle of the iris in both eyes, resulting in pupils that are less than 2 mm in diameter. A family 
from the United States was identified by Dr. Fan with microcoria and progressive proximal 
skeletal muscle weakness; the symptoms in this family were consistent with a limb-girdle 
muscular dystrophy (LGMD).  
Previous studies have linked chromosome 13q31-33 to microcoria (2,3); however, 
microcoria is also believed to be characterized by genetic heterogeneity(4-5). Thus, this study set 
out to identify the locus responsible for this familial case of microcoria myopathy through a 
conventional genome-wide linkage study. The linkage study was followed by whole exome 
sequencing (WES) and whole genome sequencing (WGS) to identify putative causative 
mutation(s). Furthermore, WES was performed for 7 exomes from unrelated patients, all from 
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different families, presenting with either a tubular aggregate myopathy or familial pinpoint 
pupils. 
Genome-wide linkage studies have identified over 1,200 chromosomal regions containing 
rare variants that contribute to the etiology of various disorders, most of which are Mendelian. 
Although the advent of genome-wide single nucleotide polymorphism (SNP) genotyping has 
increased the resolution achieved by linkage studies, it is uncommon for the linkage support 
interval not to contain hundreds of genes. While there has been a modicum of success in 
understanding the underlying genetics of more complex phenotypes than those engendered by 
single mutation Mendelian diseases, new approaches are needed to determine the genes 
responsible for the majority of human diseases (6).  
The realization of the goals of the Human Genome Project and the advent of next-
generation, massively parallel sequencing technologies may be the key to improving our 
understanding of the genetics of disease. Massively parallel sequencing (MPS) allows for the 
identification of causal mutations in human diseases, greatly enhancing the resolution of 
traditional linkage and association studies. WES has enabled the successful identification of 
many mutations that cause single-gene, Mendelian disorders (7-10).  
This study integrated genome-wide linkage analysis and MPS in order to determine the 
mutation responsible for a familial microcoria myopathy. Linkage suggested that the causative 
mutation was located on Chromosome 5q35. WES revealed that the affected individuals in the 
pedigree all shared a missense mutation in C5orf60 and that 5 of 7 unrelated subjects presenting 
with either a myopathy with tubular aggregates or pinpoint pupils also had missense mutations at 
this locus. In the 7 unrelated subjects, WES also identified additional mutations in genes 
previously implicated in myopathies including  MACF1, ANO-5, PLEC, TTN, SBCB, and FLNC. 
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5.2 Methods 
Subjects and Samples 
A family affected by a myopathy characterized by progressive muscle wasting and 
microcoria was identified and assessed by Dr. Fan (Figure 5.1).  
 Genomic DNA (gDNA) was extracted from peripheral blood samples from 12 family members 
using a Puregene Blood Core kit (Qiagen, Valencia, California) according to the manufacturer’s 
instructions, and the concentration of DNA was quantified with a spectrophotometer (NanoDrop, 
Wilmington, Delaware).  
Seven DNA samples from subjects, all from different families, from the United 
Kingdom, identified by Dr. Houlden, who were affected by tubular aggregate myopathies or 
microcoria were used in the exome sequencing phase of the study. 
This study was conducted in accordance with the guidelines of the Institutional Review Board of 
the University of North Carolina at Chapel Hill (IRB Study #07-1001). All subjects provided 
informed consent. 
 
SNP Genotyping 
All gDNA samples from the affected family were genotyped on the Affymetrix Genome-
Wide Human SNP Array 6.0 platform according to the manufacturer’s protocol, and the 
genotype calls were made using the Birdseed V2 algorithm included in the Affymetrix 
Genotyping Console software package (Affymetrix, Santa Clara, California). 
Standard quality control measures were used to filter the single nucleotide polymorphism  
genotyping calls with the PLINK software(11). Only potentially informative SNPs (i.e., those for 
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which all subjects did not have the same genotype) with genotyping rates > 90% were included. 
After filtering, there were 442,393 SNPs left for analysis. 
 
Genome-wide Linkage Analysis 
Singlepoint linkage analysis was performed in Merlin(12), assuming a fully penetrant, 
autosomal dominant model of disease. This model of inheritance was plausible because there 
were affected subjects in all generations. The genotypes were checked for Mendelian 
inconsistencies using the Merlin error checking function (--error). Because linkage 
disequilibrium (LD) between SNPs can inflate LOD scores, LD was modeled in Merlin before 
performing the analysis. To exclude false positive linkage signals that were the result of incorrect 
genotyping calls, the genotyping cluster plots for SNPs located in the chromosomal regions with 
the highest LOD scores were examined (described above)  Once incorrectly called markers had 
been excluded, multipoint linkage analysis was performed in the regions of interest with Merlin 
with error checking and linkage disequilibrium modeling. 
 
Haplotype Analysis 
The haplotypes for each subject were phased in Merlin, and the haplotype that was shared 
among the affected subjects in the region with the highest LOD score was determined. 
 
Whole Genome Sequencing 
Five micrograms of gDNA from 1 affected subject was used to construct a shotgun 
library for MPS. An Illumina Genome Analyzer II (Illumina, San Diego, CA) was used to 
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generate 76 bp paired-end reads with the standard primer, according to the manufacturer’s 
recommendations.  
 
Whole Exome Sequencing 
Twelve exomes were sequenced through targeted capture and MPS. The targeted capture 
was performed with the Nextera Exome Capture Kit (Illumina, San Diego, CA). Briefly, 10 ng of 
genomic DNA were simultaneously fragmented and tagged with adaptors. After cleaning up the 
resulting “tagmented” DNA with bead size selection, the sequencing primers were ligated to the 
DNA fragments. The sample was then PCR-amplified and denatured to allow for the 
hybridization of biotinylated probes to the targeted regions of the exome. The targeted DNA 
library was then captured with streptavidin beads and eluted. The hybridization and elution steps 
were repeated. An Illumina HiSeq 2500 on the rapid run setting was used to generate 100-bp 
paired end reads.  
 
Read Alignment, Variant Calling, and Variant Annotation 
The sequence reads were separately mapped against the reference genome, UCSC 
assembly h19 (NCBI build 37.1), using the Burrows-Wheeler Aligner (BWA) software (13). The 
paired-end reads were then mapped to each other with BWA. The resulting SAM (Sequence 
Alignment/Map) file was then sorted, converted into a BAM (binary SAM) file, and indexed 
using the SAMtools software package (14). Reads resulting from duplicate PCR molecules were 
removed with the MarkDuplicates function in the Picard software package (15). The resulting 
BAM file was indexed and submitted to the Genome Analysis Toolkit (16) Variant Detection 
pipeline. After realigning around indels, the variants were called in the Unified Genotyper and 
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listed in a variant call format (VCF) file for further analysis.(17)  The VCF file was annotated 
using the SeattleSeq annotation pipeline. 
Because common variants were not believed to explain the disease, variants were 
excluded for having a minor allele frequency greater than 0.5%. The minor allele frequencies 
were derived from the Exome Sequencing Project (ESP) Exome Variant Server data and/or from 
the 1000 Genomes Project data. The analysis was limited to variants that were shared by all 5 
affected family members. Priority was given to variants that were determined to be potentially 
damaging; this included variants that were rated as being possibly or probably damaging by 
Polyphen as well as splice site variants and nonsense variants. 
 
5.3 Results 
Clinical History 
A family affected by a mild to moderate limb-girdle muscular dystrophy and microcoria 
was identified; the two conditions co-existed in all affected family members. All affected 
subjects also presented with calf muscle hypertrophy. There were phenotypical variations in this 
family; two male subjects (II-1 and II-3) had moderate to severe LGMD and became wheelchair 
bound in their early 50’s and late 40’s respectively. I-1 had a milder LGMD phenotype; she was 
still ambulatory in her 70’s. All these affected members had moderately elevated creatine kinase 
(CK) levels, in the range of 1100 – 2400. Both I-1 and II-1 had muscle biopsies that showed 
increased fiber size variation, increased central nuclei, some degenerating and regenerating 
fibers. No inflammatory infiltrate. No aggregates seen. However, these two muscle biopsies were 
limited, and most were adipose tissue. Every affected subject had microcoria that was less severe 
in infancy/early childhood, but that became pinpoint while they were of school age. 
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Ophthalmological examination revealed normal iris structures without stromal thinning, pupils at 
a size of 1 mm baseline, minimal pupillary constriction to bright light and minimal dilation in 
darkness. Only 1 mm dilation of the pupils OU to Mydriacyl and Neosynephrine suggests 
damage localized to the pupillary sphincter muscles and the pupillary dilator. There were also 
additional phenotypes that included severe migraines in subject II-4 and epilepsy in III-1.  
 
Genome-wide Linkage Analysis 
A genome-wide linkage analysis was performed using single nucleotide polymorphism 
data to determine where the potential causative mutation(s) for the microcoria myopathy might 
be localized. The pedigree suggested an autosomal dominant model of disease as there were 
affected subjects in each generation.  
The results of the genome-wide linkage analysis are presented in Figure 5.2. An 
approximately 24 cM chromosomal region, on Chromosome 5q35, showed linkage to microcoria 
myopathy (LOD =1.8) While this LOD score is below the conventional threshold for proving 
linkage, the rest of the genome had been excluded. All other regions of the genome had LOD 
scores less than 0. Haplotype analysis allowed the confirmation of the affection status of the 
subjects because the haplotype sharing in the region of interest was exclusive to the affected 
subjects. The affected subjects shared a haplotype that was approximately 25 cM in length. The 
approximate expected length of sharing between 2 related subjects is defined by the equation 200 
cM/(2n+1), where n= the number of meioses.(18) Thus, the determined length of sharing was 
reasonably close to the predicted haplotype length of 28.71 cM.  
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Whole Genome Sequencing 
WGS was performed for 1 subject from the affected family to identify potentially 
causative mutations (see Figure 5.1) An Illumina Genome Analyzer II was used to generate 76 
bp paired-end reads that were then mapped to the reference genome with the BWA software. 
Overall, 1,014,987,470 reads were obtained for the subject (henceforth Subject I-1)  The average 
coverage throughout the genome was 24.52X, and in the linked region on chromosome 5, the 
average coverage was 36.30X for Subject I-1.  
Once the base pairs had been called and aligned, the search for potentially causative 
variants excluded variants with a minor allele frequency greater than 0.5%. The variant analysis 
focused on the distal region of Chromosome 5 because the linkage analysis had excluded the rest 
of the genome. In this particular region, there were 7 rare variants for Subject I-1. The variants 
were further stratified based on their predicted effect. For the purpose of this study, “potentially 
damaging” mutations included any missense variants that were predicted to be either possibly or 
probably damaging by Polyphen as well as splice variants and nonsense variants.  
The subject was found to have a potentially damaging missense mutation in C5orf60 
(c.97C>T) that resulted in the conversion of a proline to a serine (p.Pro33Ser) This mutation was 
classified as “probably damaging” by Polyphen and was not present in the ESP database, 
suggesting that this variant was not present in the general population. Furthermore, this variant 
was not present in hundreds of exomes sequenced at UNC-Chapel Hill. The mutation occurred in 
the first exon of C5orf60; within this particular exon, the ESP database indicated that there were 
only two other rare variants, but both of these variants were predicted to be benign. In the other 
exons in C5orf60, there was only one rare variant that was predicted to be potentially damaging 
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in the ESP database; the p.L92S variant was predicted to be possibly damaging and occurred in 
one sequenced exome. Figure 3 displays the variants found in this study, as well as the other rare 
missense variants at this locus.  
 
Whole Exome Sequencing 
To supplement the findings of the WGS, WES was carried out on the 5 affected subjects 
(see Figure 5.1) and 7 unrelated subjects (listed as Subjects 6-12) from the UK also presenting 
with either tubular aggregate myopathies or microcoria. The exome sequence data were aligned 
to the reference genome and called for variants. The mean coverage for the entire exome for all 
samples was 25.82X; additional coverage data are available in Table 5.1. Variants with a minor 
allele frequency less than 0.5% and a predicted Polyphen effect of possibly or probably 
damaging, as well as splice site variants and nonsense variants, were given priority in the 
analysis. 
The 5 related subjects all shared the c.97C>T variant detected in C5orf60 by WGS. In the 
region of interest on chromosome 5, no other rare variants were shared that were predicted to be 
potentially damaging. In addition, the entire exome was interrogated for rare, potentially 
damaging variants that were shared by all affected family members. One such variant was found 
in MYOM1: p.S618T. However, the affected individuals did not share a haplotype in this region 
on chromosome 18; thus, this variant is likely to be a sequencing error. 
The exome of one of the unrelated subjects, Subject 12, also possessed the c.97C>T 
mutation in C5orf60. Another mutation in C5orf60, c.64G>C, was detected in the exomes of 
Subjects 6, 8, 10, 11, and 12. These mutations were not present in the ESP database or in 
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hundreds of exomes sequenced at UNC-Chapel Hill. Thus, 5 of the 7 unrelated subjects had at 
least one potentially damaging mutation in C5orf60. 
As 2 of the unrelated subjects did not have potentially damaging mutations in C5orf60, 
the exomes of the 7 unrelated subjects were further analyzed for variants that could be implicated 
in a myopathy or microcoria. Several potentially interesting variants were found. For example, 
three subjects had rare, potentially damaging variants (c.299A>G, c.3731G<T, c.8941G>T) in 
MACF1 (microtubule-actin cross-linking factor 1); mutations in this gene have recently been 
implicated as a novel cause of myopathies(19). Variants were also detected in genes that have 
been implicated in muscular dystrophies by linkage studies: ANO-5, FLNC, NEB, PLEC, SGCB 
and TTN. It should be noted that the related individuals from the study family did not have any 
mutations in these genes or other genes previously implicated in LGMDs that segregated with 
the disease. These results are further summarized in Table 5.2.  
 
5.4 Discussion 
This study mapped a familial microcoria myopathy locus to chromosome 5q35. This 
discovery is novel because congenital microcorias had previously been linked to 13q31-33, 
though genetic heterogeneity has been indicated by other groups as well (4,5) . 
The results of the WGS detected a missense mutation (c.97C>T) in the first exon of 
C5orf60 that was predicted to be probably damaging by Polyphen. This mutation was not present 
in the ESP database. Data from the ESP indicated the presence of only one other rare, potentially 
damaging variant at the C5orf60 locus. The infrequent occurrence of other rare, potentially 
damaging mutations at this locus strengthens the possibility that the mutation found in this study 
is indeed causative. This evidence was further bolstered by the discovery of another potentially 
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damaging mutation in the first exon of this gene in 5 unrelated subjects presenting with tubular 
aggregate myopathies or microcoria. Both of the amino acid residues affected by the mutations 
in this study are located within a predicted transmembrane domain in the translated protein.  
Transmembrane proteins play an important role in muscle tissue. For example, the 
dystrophin glycoprotein complex connects the cytoskeleton to the extracellular matrix. In muscle 
cells, the sarcoglycan proteins, which each have a single transmembrane domain, are part of this 
complex. Mutations in the sarcoglycan genes can cause limb-girdle muscular dystrophies. Thus, 
the presence of a transmembrane domain in the product of C5orf60 suggests that it might play a 
similar role in muscle. 
C5orf60 is predicted to encode a single-pass membrane protein; the full length product is 
predicted to be 353 amino acids in length. Currently, there is evidence at the transcript level for 
this protein; this evidence includes both expressed sequence tags (EST) and poly-adenylation 
sequencing (PA-seq) data from the NCBI EST and SRA databases, respectively. A BLAST 
search for the first exon against PA-seq data for human skeletal muscle (Accession number: 
SRX208129) indicated that the transcript for this gene is expressed in human skeletal muscle. 
More research is needed to determine which transcripts for this gene are expressed at the protein 
level and to understand how mutations in this gene might contribute to the microcoria myopathy 
phenotype.  
Because not all of the subjects had mutations in C5orf60, the findings of this study also 
indicated that this particular myopathy could be characterized by locus heterogeneity. In addition 
to the mutations found in C5orf60, the exome sequencing data for the 7 unrelated subjects 
indicated the presence of rare, potentially damaging mutations in several different genes, 
including genes that had previously been implicated in muscular dystrophies and other 
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myopathies. These findings underscore the genetic heterogeneity of muscular dystrophies. For 
example, three of the subjects had rare, potentially damaging variants in Macrophin-1 (MACF1), 
a gene which has recently been implicated in myopathies(19). The protein encoded by this gene 
is similar in structure and function to plectin and dystrophin (20); it acts as a microtubule and 
actin crosslinking factor. The three detected variants (c.299A>G, c.3731G<T, c.8941G>T) were 
all classified by Polyphen as being either possibly or probably damaging.   
While in silico methods might indicate that a discovered mutation is potentially 
damaging, the effect of a mutation must be assessed at the level of the individual amino acid 
residue and at the level of the gene as a whole. Several methods have been developed to 
determine how conserved a residue is and the predicted effect that a change in the residue will 
have on the protein. At the level of the gene, it has become clear that some genes are more 
“tolerant” of mutations than others (21). For example, many rare, potentially damaging variants 
have been detected in olfactory receptor genes, but these variants are typically not pathological. 
By examining the occurrence of other rare, potentially damaging variants near the mutations 
detected by exome sequencing, this study sought to qualitatively determine which genes were 
more “tolerant” than others. The C5orf60 locus was found to feature only one other possibly 
damaging variant besides the study mutations, suggesting that this locus is relatively intolerant to 
mutation. However, to determine whether the mutations found in C5orf60 are truly the cause of 
the microcoria myopathy, in vivo functional studies will need to be pursued.  
MPS technologies will continue to be used to determine the genetic causes of Mendelian 
diseases that cannot be resolved by linkage analysis alone. The next challenge lies in 
characterizing the mutations discovered by MPS approaches to determine which mutations 
contribute to disease. 
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Figure 5.1: Pedigree of a family presenting with microcoria and progressive muscle weakness in 
a limb-girdle distribution. A blue star to the left of a subject indicates that the subject’s DNA 
sample was submitted to whole genome sequencing, and a red star indicates that the subject’s 
DNA was submitted to whole exome sequencing. 
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Figure 5.2: Multipoint LOD scores between microcoria myopathy and 515 markers on 
Chromosome 5. The highest multipoint LOD score (1.8) was seen on 5q35, while the rest of the 
genome was excluded. 
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Figure 5.3: Missense mutations detected in C5orf60 by massively parallel sequencing. Two 
missense mutations in the first exon of C5orf60 were detected in a pedigree presenting with a 
microcoria myopathy as well as 5 unrelated individuals presenting with either a tubular 
aggregate myopathy or microcoria. These mutations were not in the Exome Sequencing Project 
Exome Variant Server and were also not detected in hundreds of exomes sequenced at UNC-
Chapel Hill. The dashed lines represent the study mutations, and the solid lines represent variants 
(and their predicted effects) from the Exome Variant Server in the first exon (a) and throughout 
the entire locus (b) of C5orf60. The heights of the variant lines correspond to the negative logs of 
their minor allele frequencies, except in the case of the study mutations, which were assumed to 
have a minor allele frequency of 0. The black boxes along the bottom indicate exons, while the 
horizontal lines indicate introns. The p.P33S mutation was detected in the studied pedigree, and 
the p.D22H mutation was detected in 5 unrelated subjects presenting with related phenotypes.  
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Figure 5.3 (continued) 
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Table 5.1: Mean Coverage of Massively Parallel Sequencing Data 
 Exome Sequencing Whole Genome Sequencing 
Subject Genome Chr 5q35 C5orf60 Genome Chr 5q35 C5orf60 
Subject I-1 30.61 32.43 28.83 24.52 36.30 34.83 
Subject II-1 24.78 26.90 24.39 --- --- --- 
Subject II-4 20.39 21.79 18.77 --- --- --- 
Subject III-3 22.20 23.83 22.08 --- --- --- 
Subject III-4 27.59 30.60 31.52 --- --- --- 
Subject 6 28.88 30.65 25.37 --- --- --- 
Subject 7 30.96 32.66 23.07 --- --- --- 
Subject 8 25.37 27.80 24.21 --- --- --- 
Subject 9 21.68 24.38 24.54 --- --- --- 
Subject 10 28.92 30.80 21.99 --- --- --- 
Subject 11 30.04 32.43 29.29 --- --- --- 
Subject 12 18.38 19.09 22.13 --- --- --- 
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Table 5.2: Potentially Damaging Variants Detected by Massively Parallel Sequencing 
 
Locus Variant MAF Family Sub.6 Sub.7 Sub.8 Sub.9 Sub.10 Sub.11 Sub.12 
C5orf60 c.97C>T 0         
 c.64G>C 0         
ANO-5 c.680G>C 0         
FLNC c.2068T>C 0.000715         
MACF1 c.299A>G 0.000233         
 c.3731G>T 0.002331         
 c.8941G>T 0.002098         
NEB c.18175A>G 0.000121         
PLEC c.8201C>T 0.001677         
SGCB c.800C>T 0         
TTN c.62066G>A 0.000239         
 c.13879G>T 0.000492         
 c.16603A>T 0.000487         
MAF=minor allele frequency; Sub.=subject
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Chapter 6  
Conclusions 
This work describes approaches for discovering genetic variants that contribute to the 
etiology of human diseases with complex and simple modes of inheritance through the use of 
linkage analysis, genome-wide association analysis, and massively parallel sequencing. Linkage 
analysis and genome-wide association analysis have been successful in identifying thousands of 
loci that contribute to human traits. The advent of MPS has made it possible to capture nearly all 
of the variants within the human genome has greatly accelerated the process of identifying causal 
variants. The studies contained in this work illustrate both the capabilities and limitations of 
these approaches.       
Within this work, the GWA studies of idiopathic Parkinson’s disease and dystonia 
demonstrated that the power to detect associations can be increased by reducing genetic and 
population heterogeneity. The studies of FTD-ALS and microcoria myopathy explored how 
linkage analysis and MPS approaches can be combined to analyze the genetics of familial 
diseases. The subsequent section will describe future directions that are specific to the studies 
described herein and provide context.    
 
6.1 Study-Specific Conclusions and Future Directions 
The four studies in this dissertation can be divided into two groups. Chapters 2 and 3 
describe GWA studies of complex diseases, while Chapters 4 and 5 describe studies of 
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Mendelian diseases that incorporate both linkage analysis and MPS. Chapter 1 described how a 
GWA study of idiopathic Parkinson’s disease (IPD) was able to confirm the previously reported 
association with the LRRK2 locus. In the preliminary study of 96 cases, 25 G2019S-positive 
cases, and 96 controls from an Ashkenazi Jewish population, no associations reached genome-
wide significance, but some associations were characterized by near genome-wide significance. 
To complement the findings of this preliminary study, a replication GWA study of 161 cases and 
1,404 controls from the same Ashkenazi Jewish population was performed, and additional 
genotypes were imputed. This replication study was able to detect an association signal that 
approached genome-wide significance across chromosome 12q12, including the LRRK2 locus 
(average p-value=4.85 x 10
-6
). Furthermore, two SNPs in an intergenic region upstream of 
LRRK2 on chromosome 12pq11.21 were found to have association signals with genome-wide 
significance: rs10506095 (p= 2.49x10-10) and rs7316771(p=1.19x10-9). A previous GWAS of 
IPD performed in a Japanese population also found significant associations for SNPs that were 
upstream of LRRK2. One possibility is that upstream variants influence the transcriptional 
regulation of LRRK2, which is believed to induce neuronal toxicity or that the variants are in 
linkage disequilibrium with the causal variants. However, the detection of an association signal 
upstream of LRRK2 also opens up the possibility that genes besides LRRK2 in this region on 
chromosome 12, such as SLC2A13, may be may play a role in susceptibility to IPD.  
By reducing population heterogeneity and including a substantial proportion of known 
LRRK2 mutation carriers, this study demonstrated how genetic heterogeneity may have 
prevented previous GWA studies from detecting an association signal in the LRRK2 region. 
While GWA studies have moved in the direction of having larger sample sizes, it is crucial to 
account for population heterogeneity. For example, research has shown that in the Ashkenazi 
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Jewish population studied in this work, LRRK2 G2019S mutation carriers share a haplotype from 
a recent common ancestor. Thus, future studies of IPD in this population should make use of this 
knowledge by stratifying subjects based on LRRK2 mutation status. Other studies have 
exemplified this point by demonstrating that alleles associated with IPD in genes such as MAPT 
and SNCA occur at different frequencies in different populations. While GWA studies have 
identified many common variants in IPD, it will also be crucial to identify rare mutations that 
contribute to the genetic etiology of this disease. Thus, future studies of IPD will most likely 
make use of MPS technologies to provide a better understanding of this polygenic disease. 
This work also contains one of the first GWA studies of dystonia. While there have been 
several linkage studies of this group of syndromes, GWA studies posed the challenge of 
collecting a sufficient number of samples to ensure adequate power. Because of the relatively 
small sample size, this study was predicted to have enough power to detect a variant with a 
comparatively larger effect size. As in the GWA study of IPD, the ability to detect an association 
was also strengthened by the use of a population with less admixture. This study found an 
association signal with genome-wide significance on chromosome 17q25.3 within an intronic 
region of RNF213 at two genotyped markers, rs12601730 (p =2.40 x 10
-9
, OR = 2.169) and 
rs12603583 (p=2.61 x 10
-9
, OR=1.942), as well as two imputed markers, rs4889968 (p=2.61 x 
10
-9
, OR=1.942) and rs9902013 (p=3.84 x10
-9
), which were all in LD. RNF213 is known to be 
expressed in the cerebellum, and its expression in the basal ganglia further strengthens its 
potential involvement in the genetic etiology of dystonia. To confirm this finding, additional 
samples should be collected for a replication GWA study or for whole genome sequencing to 
identify potentially causative mutations at this locus and at other loci throughout the genome. 
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Thus, the two GWA studies in this work illustrated the ability to identify loci of interest for 
future study by minimizing the genetic heterogeneity of the study population. 
This work also explored the application of MPS technologies. Both whole genome and 
whole exome sequencing were used to analyze the case of frontotemporal dementia with 
amyotrophic lateral sclerosis (FTD-ALS) in family San Francisco-A. Many recent studies have 
identified a hexanucleotide repeat expansion in C9orf72 as being the cause of both familial and 
sporadic cases of FTD and/or ALS. Linkage analysis and repeat-primed PCR, however, excluded 
this region in family San Francisco-A. While a previous linkage study of this family using 
microsatellite data identified a linkage signal on chromosome 17q, the diagnostic status of two 
individuals had changed since this first report. Thus, the exome sequencing data from FTD-ALS 
family San Francisco-A were used to perform a multipoint linkage analysis, which excluded 17q 
and instead potentially implicated chromosome 9q in this family. In this region, all affected 
family members shared a synonymous mutation in CRB2, a gene in the gamma-secretase 
pathway. No other rare variants were shared by all affected family members in the region of 
linkage. If the discovered mutation in CRB2 is in fact causative, it may influence gene 
expression; functional studies to quantify both RNA and protein expression could test this 
hypothesis. Additionally, because of the role that repeat expansions have been shown to play in 
the genetics of neurodegenerative diseases, it may be useful to perform additional whole genome 
sequencing of subjects from family San Francisco-A on the Pacific Biosciences platform, which 
produces sequence reads several thousand nucleotides in length. The shorter read lengths (100 
bp) produced by the Illumina sequencing technologies used in the current report likely prevented 
the detection of repeat expansions in the whole genome sequencing data. Thus, functional 
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characterization of the detected CRB2 mutation and additional sequencing could help to 
complete the picture of the genetics of FTD-ALS in family San Francisco-A. 
MPS was also used to investigate the genetics of a microcoria myopathy in one family 
with 5 affected individuals and in 7 unrelated individuals. This study identified a potentially 
causative variant in C5orf60 in a three-generation family affected by progressive muscle 
weakness in a limb-girdle distribution and microcoria. While some previous studies had 
demonstrated that microcoria was linked to chromosome 13q, other studies had indicated that 
this condition was characterized by genetic heterogeneity.  
To determine whether microcoriawas linked to 13q in the study family, twelve members 
of the affected family (5 affected and 7 unaffected) were genotyped for 909,622 single 
nucleotide polymorphisms for a multipoint linkage analysis. The linkage analysis found a 
multipoint LOD score of 1.8 located within a 25 cM region on Chromosome 5q35. While this 
LOD score was below the threshold conventionally used as a criterion to declare linkage, the rest 
of the genome, including chromosome 13q, was excluded. All of the affected subjects shared a 
haplotype in the region that was not shared by any of the unaffected subjects. 
Massively parallel DNA sequencing for the five affected subjects detected a missense 
mutation on chromosome 5q35 in C5orf60: c.97C>T (p.P33S). Whole exome sequencing was 
also performed for 7 unrelated subjects, all from different families, affected with tubular 
aggregate myopathies and/or microcoria. The c.97C>T variant in C5orf60 was found in 1 of the 
unrelated subjects. Another missense mutation in C5orf60, c.64G>C (p.D22H), was present in 
the exomes from 5 of the unrelated subjects. The exome of 1 unrelated subject had both of these 
variants. Thus, 5 of the 7 unrelated subjects had at least 1 mutation in C5orf60. In the 7 unrelated 
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subjects, exome sequencing also detected additional mutations or very rare variants in genes 
previously implicated in myopathies including  MACF1, ANO-5, PLEC, TTN, SBCB, and FLNC. 
These findings are significant because they corroborate the findings of other researchers 
that microcoria is characterized by genetic heterogeneity and because they demonstrate that 
mutations in C5orf60 represent a novel potential cause of microcoria myopathy. Future studies 
could focus on characterizing the effect that mutations in C5orf60 have on gene expression and 
the role that this locus plays in the muscle biology.  
 
6.2 Insights and Context 
While GWA studies have implicated thousands of loci in hundreds of phenotypes, several 
criticisms of the findings of GWA studies have been made. First, while the p-values of GWA 
signals achieve genome-wide significance, it is difficult to understand what this high level of 
significance means. It has been speculated that many of these significant association signals may 
be false positives. There has also been debate over the possibility that these associations are 
actually the result of rare variants that are in LD with common variants (Dickson et al., 2010). In 
the study of type 2 diabetes, for example, several genes have been implicated repeatedly by 
GWA studies, such as TCF7L2 and PPARG. The GWA study of idiopathic Parkinson’s disease 
in this work provided further confirmation of the role of LRRK2 mutations in the etiology of the 
disease. The reproducibility of GWA studies points to their robustness and the accuracy of their 
findings.        
Second, part of the dissatisfaction with GWA studies stems from the difficulty in 
attributing significance to the findings. Even when association signals with genome-wide 
significance are replicated by multiple studies, it is difficult to know how these associated 
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variants contribute to the underlying biology of a phenotype. Most of the variants implicated by 
GWA studies do not cause an obvious change in a protein. Some are even located hundreds of 
thousands of base pairs from any known gene. While variants implicated in GWA studies that do 
not cause an amino acid change could simply be “tagging” other variants, these findings may 
also suggest that the current focus on variants that cause changes in proteins is too narrow. 
Protein-coding sequences make up less than 2% of the genome, and the findings of GWA studies 
suggest that the other 98% can play a major role in phenotypic variation. Thus, the findings of 
GWA studies prompted researchers to investigate how variants can affect gene expression; these 
expression quantitative trait loci (eQTLs) can either effect the expression of the nearest gene 
(cis-eQTLs) or a gene located thousands of base pairs away (trans-eQTLs).       
Third, despite the ability to genotype approximately one million markers in ever-larger 
cohorts, GWA studies have not identified common variants with large effect sizes (McClellan 
and King, 2010). GWA studies have largely not improved medicine’s ability to predict an 
individual’s risk for common diseases. However, the discovery of these variants has allowed the 
implication of previously unexplored biological pathways in common disease and identified 
pathways that are common to multiple complex diseases. A better understanding of these 
pathways will likely yield new therapeutic targets.  Therefore, even if associations detected by 
GWA studies did not contribute to the prediction of disease risk, they may provide important 
insights into the biology and potential treatment of complex diseases.            
Despite these criticisms, when considered collectively, GWA studies have greatly 
advanced the field of human genetics and have comprehensively explored the role of common 
genetic variation in complex disease. For GWA findings that were replicated by properly 
designed and sufficiently powered studies, some variant, either rare or common, that is in LD 
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with the significantly-associated SNP must be present that explains the association. Subsequent 
resequencing and functional studies can be used to identify these variants and their roles in the 
genetic etiology of a phenotype.          
MPS studies have the ability to identify nearly all the variants in an individual genome 
and to determine the mutations underlying significant GWA and linkage signals. This great 
potential, however, comes with its own set of challenges. 
Because each sequenced genome results in gigabytes of data, many of the challenges 
associated with MPS approaches involve data management and bioinformatics. As was discussed 
in the introduction, an important consideration is the selection of the alignment and variant 
calling algorithms. In the analysis of MPS data, a paradox has arisen because alignment and 
variant calling software relies on the similarities between the sequence reads and the reference 
genome, but researchers are interested in the differences. The problem lies in distinguishing 
“errors” from actual variants. New alignment algorithms are developed regularly, but more work 
is needed to understand which of these algorithms provides the best balance between 
computational speed and accuracy. The inability of the alignment software to unambiguously 
match a sequence read to the genome can result in the substantial loss of data. As the depth of 
sequencing and the length of sequence reads increase, this problem will likely be less of an issue. 
Variant calling software is prone to both type I and type II error. Type I error can be reduced by 
increasing read depth and performing recalibration steps (Jia et al., 2012), but better variant 
calling methods are needed to reduce type II error and provide greater sensitivity for rare 
variants.   
Another challenge for MPS studies is the functional characterization of causal variants. 
The current focus of MPS studies is the exome. Yet the exome only makes up about 1% of the 
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genome. Emerging data are suggesting that even in the case of Mendelian diseases for which the 
causal variant is suspected to have a high penetrance, exome sequencing may not be sufficient to 
identify the causal variant. This observation was exemplified by the FTD-ALS family study in 
this work; exome sequencing was unable to detect an obvious deleterious mutation. This failure 
can be explained in one of two ways: either the causal mutation is not located in the exome or the 
synonymous variant found in CRB2 in the affected individuals affects gene expression. More 
effort is needed to identify and to understand the impact of variants besides those that cause a 
change in the amino acid sequence of a protein.    
Furthermore, current approaches to MPS analysis are lacking in the ability to align large 
copy number variants and repetitive sequences. When a sequence occurs more than once in the 
reference genome, it is difficult for aligning software to unambiguously match a read to the 
reference. In the case of CNVs, experience from GWA studies of neuropsychiatric disorders, 
such as autism and schizophrenia, suggests that novel CNVs can play a very important role in the 
genetic etiology of a disease. Thus, the scope and analytical power of MPS approaches need to 
be expanded to account for a wider variety of variants. These ends can be achieved by pursuing 
whole genome sequencing with longer sequence reads and by improving both in vivo and in 
silico methods for characterizing causal variants. 
 
6.3 Final Thoughts 
The purpose of this work was to use linkage analysis, association analysis, and MPS 
approaches to interrogate the genetic etiology of both Mendelian and complex human diseases. 
The studies presented in this work demonstrate both the potential and drawbacks of these 
approaches.  Linkage and association analysis have collectively improved our understanding of 
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the biology of thousands of human diseases and paved the path forward for understanding the 
genetics of human disease. MPS approaches have proven their utility in the identification of 
causal variants for Mendelian diseases, and their ability to identify causal mutations in complex 
diseases will be tested in the near future. MPS approaches, in combination with linkage and 
association analysis, will continue to be leveraged to identify variants that contribute to traits of 
medical importance. 
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